{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["cancer", "immunotherapy", "mTOR", "mTOR inhibitors", "natural drugs"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36428613", "DateRevised": {"Year": "2022", "Month": "12", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "11", "Day": "10"}], "Language": ["eng"], "ELocationID": ["5520", "10.3390/cancers14225520"], "Journal": {"ISSN": "2072-6694", "JournalIssue": {"Volume": "14", "Issue": "22", "PubDate": {"Year": "2022", "Month": "Nov", "Day": "10"}}, "Title": "Cancers", "ISOAbbreviation": "Cancers (Basel)"}, "ArticleTitle": "Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy.", "Abstract": {"AbstractText": ["The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine-protein kinase, which regulates many biological processes related to metabolism, cancer, immune function, and aging. It is an essential protein kinase that belongs to the phosphoinositide-3-kinase (PI3K) family and has two known signaling complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Even though mTOR signaling plays a critical role in promoting mitochondria-related protein synthesis, suppressing the catabolic process of autophagy, contributing to lipid metabolism, engaging in ribosome formation, and acting as a critical regulator of mRNA translation, it remains one of the significant signaling systems involved in the tumor process, particularly in apoptosis, cell cycle, and cancer cell proliferation. Therefore, the mTOR signaling system could be suggested as a cancer biomarker, and its targeting is important in anti-tumor therapy research. Indeed, its dysregulation is involved in different types of cancers such as colon, neck, cervical, head, lung, breast, reproductive, and bone cancers, as well as nasopharyngeal carcinoma. Moreover, recent investigations showed that targeting mTOR could be considered as cancer therapy. Accordingly, this review presents an overview of recent developments associated with the mTOR signaling pathway and its molecular involvement in various human cancer types. It also summarizes the research progress of different mTOR inhibitors, including natural and synthetised compounds and their main mechanisms, as well as the rational combinations with immunotherapies."]}, "AuthorList": [{"Identifier": ["0000-0001-9317-1631"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Human Pathologies Biology, Department of Biology, Faculty of Sciences, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat 10106, Morocco."}], "LastName": "Bouyahya", "ForeName": "Abdelhakim", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Immunology, Yale University School of Medicine, 333 Cedars Street, TAC S610, New Haven, CT 06519, USA."}], "LastName": "El Allam", "ForeName": "Aicha", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Physiology and Physiopathology Team, Faculty of Sciences, Genomic of Human Pathologies Research, Mohammed V University in Rabat, Rabat 10106, Morocco."}], "LastName": "Aboulaghras", "ForeName": "Sara", "Initials": "S"}, {"Identifier": ["0000-0002-4521-3515"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Geo-Bio-Environment Engineering and Innovation Laboratory, Molecular Engineering, Biotechnologies and Innovation Team, Polydisciplinary Faculty of Taroudant, Ibn Zohr University, Agadir 80000, Morocco."}], "LastName": "Bakrim", "ForeName": "Saad", "Initials": "S"}, {"Identifier": ["0000-0002-4842-2056"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Pharmacology, National Agency of Medicinal and Aromatic Plants, Taounate 34025, Morocco."}], "LastName": "El Menyiy", "ForeName": "Naoual", "Initials": "N"}, {"Identifier": ["0000-0002-9387-5492"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, 1988, Najran 61441, Saudi Arabia."}], "LastName": "Alshahrani", "ForeName": "Mohammed Merae", "Initials": "MM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, 1988, Najran 61441, Saudi Arabia."}], "LastName": "Al Awadh", "ForeName": "Ahmed Abdullah", "Initials": "AA"}, {"Identifier": ["0000-0001-5732-2818"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Environment and Health Team, Polydisciplinary Faculty of Safi, Cadi Ayyad University, Sidi Bouzid B.P. 4162, Morocco."}], "LastName": "Benali", "ForeName": "Taoufiq", "Initials": "T"}, {"Identifier": ["0000-0002-8589-7456"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Novel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia."}], "LastName": "Lee", "ForeName": "Learn-Han", "Initials": "LH"}, {"Identifier": ["0000-0002-0308-1155"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Histology, Embryology, and Cytogenetic, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat 10100, Morocco."}], "LastName": "El Omari", "ForeName": "Nasreddine", "Initials": "N"}, {"Identifier": ["0000-0001-6686-7019"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Data Science and Information Technology, INTI International University, Nilai 71800, Malaysia."}], "LastName": "Goh", "ForeName": "Khang Wen", "Initials": "KW"}, {"Identifier": ["0000-0002-6971-1383"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pengiran Anak Puteri Rashidah Sa'adatul Bolkiah Institute of Health Sciences, Universiti Brunei Darussalam, Gadong BE1410, Brunei."}], "LastName": "Ming", "ForeName": "Long Chiau", "Initials": "LC"}, {"Identifier": ["0000-0002-9782-0835"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, The University of Jordan, Amman 11942, Jordan."}], "LastName": "Mubarak", "ForeName": "Mohammad S", "Initials": "MS"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Cancers (Basel)", "NlmUniqueID": "101526829", "ISSNLinking": "2072-6694"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Brown E.J., Albers M.W., Bum Shin T., Keith C.T., Lane W.S., Schreiber S.L. A Mammalian Protein Targeted by G1-Arresting Rapamycin\u2013Receptor Complex. Nature. 1994;369:756\u2013758. doi: 10.1038/369756a0.", "ArticleIdList": ["10.1038/369756a0", "8008069"]}, {"Citation": "Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and Regulation of Akt/PKB by the Rictor-MTOR Complex. Science. 2005;307:1098\u20131101. doi: 10.1126/science.1106148.", "ArticleIdList": ["10.1126/science.1106148", "15718470"]}, {"Citation": "Laplante M., Sabatini D.M. MTOR Signaling in Growth Control and Disease. Cell. 2012;149:274\u2013293. doi: 10.1016/j.cell.2012.03.017.", "ArticleIdList": ["10.1016/j.cell.2012.03.017", "PMC3331679", "22500797"]}, {"Citation": "Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin Passes the Torch: A New Generation of MTOR Inhibitors. Nat. Rev. Drug Discov. 2011;10:868\u2013880. doi: 10.1038/nrd3531.", "ArticleIdList": ["10.1038/nrd3531", "22037041"]}, {"Citation": "Foster D.A. Phosphatidic Acid and Lipid-Sensing by MTOR. Trends Endocrinol. Metab. 2013;24:272\u2013278. doi: 10.1016/j.tem.2013.02.003.", "ArticleIdList": ["10.1016/j.tem.2013.02.003", "PMC3669661", "23507202"]}, {"Citation": "Huang K., Fingar D.C. Seminars in Cell & Developmental Biology. Volume 36. Elsevier; Amsterdam, The Netherlands: 2014. Growing Knowledge of the MTOR Signaling Network; pp. 79\u201390.", "ArticleIdList": ["PMC4253687", "25242279"]}, {"Citation": "Kim S.M., Vetrivel P., Ha S.E., Kim H.H., Kim J.-A., Kim G.S. Apigetrin Induces Extrinsic Apoptosis, Autophagy and G2/M Phase Cell Cycle Arrest through PI3K/AKT/MTOR Pathway in AGS Human Gastric Cancer Cell. J. Nutr. Biochem. 2020;83:108427. doi: 10.1016/j.jnutbio.2020.108427.", "ArticleIdList": ["10.1016/j.jnutbio.2020.108427", "32559585"]}, {"Citation": "Khan K., Quispe C., Javed Z., Iqbal M.J., Sadia H., Raza S., Irshad A., Salehi B., Reiner \u017d., Sharifi-Rad J. Resveratrol, Curcumin, Paclitaxel and MiRNAs Mediated Regulation of PI3K/Akt/MTOR Pathway: Go Four Better to Treat Bladder Cancer. Cancer Cell Int. 2020;20:560. doi: 10.1186/s12935-020-01660-7.", "ArticleIdList": ["10.1186/s12935-020-01660-7", "PMC7685642", "33292283"]}, {"Citation": "Mafi S., Mansoori B., Taeb S., Sadeghi H., Abbasi R., Cho W.C., Rostamzadeh D. MTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment. Front. Immunol. 2022;12:5724. doi: 10.3389/fimmu.2021.774103.", "ArticleIdList": ["10.3389/fimmu.2021.774103", "PMC8894239", "35250965"]}, {"Citation": "Thomson A.W., Turnquist H.R., Raimondi G. Immunoregulatory Functions of MTOR Inhibition. Nat. Rev. Immunol. 2009;9:324\u2013337. doi: 10.1038/nri2546.", "ArticleIdList": ["10.1038/nri2546", "PMC2847476", "19390566"]}, {"Citation": "Weichhart T., Hengstschl\u00e4ger M., Linke M. Regulation of Innate Immune Cell Function by MTOR. Nat. Rev. Immunol. 2015;15:599\u2013614. doi: 10.1038/nri3901.", "ArticleIdList": ["10.1038/nri3901", "PMC6095456", "26403194"]}, {"Citation": "Seidel J.A., Otsuka A., Kabashima K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front. Oncol. 2018;8:86. doi: 10.3389/fonc.2018.00086.", "ArticleIdList": ["10.3389/fonc.2018.00086", "PMC5883082", "29644214"]}, {"Citation": "Weber J. Seminars in Oncology. Volume 37. Elsevier; Amsterdam, The Netherlands: 2010. Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer\u2014Preclinical Background: CTLA-4 and PD-1 Blockade; pp. 430\u2013439.", "ArticleIdList": ["21074057"]}, {"Citation": "Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H. RAFT1: A Mammalian Protein That Binds to FKBP12 in a Rapamycin-Dependent Fashion and Is Homologous to Yeast TORs. Cell. 1994;78:35\u201343. doi: 10.1016/0092-8674(94)90570-3.", "ArticleIdList": ["10.1016/0092-8674(94)90570-3", "7518356"]}, {"Citation": "Sabers C.J., Martin M.M., Brunn G.J., Williams J.M., Dumont F.J., Wiederrecht G., Abraham R.T. Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells\u2217. J. Biol. Chem. 1995;270:815\u2013822. doi: 10.1074/jbc.270.2.815.", "ArticleIdList": ["10.1074/jbc.270.2.815", "7822316"]}, {"Citation": "Gingras A.-C., Raught B., Sonenberg N. Regulation of Translation Initiation by FRAP/MTOR. Genes Dev. 2001;15:807\u2013826. doi: 10.1101/gad.887201.", "ArticleIdList": ["10.1101/gad.887201", "11297505"]}, {"Citation": "Cornu M., Albert V., Hall M.N. MTOR in Aging, Metabolism, and Cancer. Curr. Opin. Genet. Dev. 2013;23:53\u201362. doi: 10.1016/j.gde.2012.12.005.", "ArticleIdList": ["10.1016/j.gde.2012.12.005", "23317514"]}, {"Citation": "Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., Yonezawa K. Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action. Cell. 2002;110:177\u2013189. doi: 10.1016/S0092-8674(02)00833-4.", "ArticleIdList": ["10.1016/S0092-8674(02)00833-4", "12150926"]}, {"Citation": "Kim D.-H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. MTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex That Signals to the Cell Growth Machinery. Cell. 2002;110:163\u2013175. doi: 10.1016/S0092-8674(02)00808-5.", "ArticleIdList": ["10.1016/S0092-8674(02)00808-5", "12150925"]}, {"Citation": "Schalm S.S., Fingar D.C., Sabatini D.M., Blenis J. TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function. Curr. Biol. 2003;13:797\u2013806. doi: 10.1016/S0960-9822(03)00329-4.", "ArticleIdList": ["10.1016/S0960-9822(03)00329-4", "12747827"]}, {"Citation": "Schalm S.S., Blenis J. Identification of a Conserved Motif Required for MTOR Signaling. Curr. Biol. 2002;12:632\u2013639. doi: 10.1016/S0960-9822(02)00762-5.", "ArticleIdList": ["10.1016/S0960-9822(02)00762-5", "11967149"]}, {"Citation": "Hay N., Sonenberg N. Upstream and Downstream of MTOR. Genes Dev. 2004;18:1926\u20131945. doi: 10.1101/gad.1212704.", "ArticleIdList": ["10.1101/gad.1212704", "15314020"]}, {"Citation": "Jansson T., Aye I.L., Goberdhan D.C. The Emerging Role of MTORC1 Signaling in Placental Nutrient-Sensing. Placenta. 2012;33:e23\u2013e29. doi: 10.1016/j.placenta.2012.05.010.", "ArticleIdList": ["10.1016/j.placenta.2012.05.010", "PMC3463762", "22687819"]}, {"Citation": "Inoki K., Li Y., Zhu T., Wu J., Guan K.-L. TSC2 Is Phosphorylated and Inhibited by Akt and Suppresses MTOR Signalling. Nat. Cell Biol. 2002;4:648\u2013657. doi: 10.1038/ncb839.", "ArticleIdList": ["10.1038/ncb839", "12172553"]}, {"Citation": "Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C. Identification of the Tuberous Sclerosis Complex-2 Tumor Suppressor Gene Product Tuberin as a Target of the Phosphoinositide 3-Kinase/Akt Pathway. Mol. Cell. 2002;10:151\u2013162. doi: 10.1016/S1097-2765(02)00568-3.", "ArticleIdList": ["10.1016/S1097-2765(02)00568-3", "12150915"]}, {"Citation": "Ballif B.A., Roux P.P., Gerber S.A., MacKeigan J.P., Blenis J., Gygi S.P. Quantitative Phosphorylation Profiling of the ERK/P90 Ribosomal S6 Kinase-Signaling Cassette and Its Targets, the Tuberous Sclerosis Tumor Suppressors. Proc. Natl. Acad. Sci. USA. 2005;102:667\u2013672. doi: 10.1073/pnas.0409143102.", "ArticleIdList": ["10.1073/pnas.0409143102", "PMC545566", "15647351"]}, {"Citation": "Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J. Tumor-Promoting Phorbol Esters and Activated Ras Inactivate the Tuberous Sclerosis Tumor Suppressor Complex via P90 Ribosomal S6 Kinase. Proc. Natl. Acad. Sci. USA. 2004;101:13489\u201313494. doi: 10.1073/pnas.0405659101.", "ArticleIdList": ["10.1073/pnas.0405659101", "PMC518784", "15342917"]}, {"Citation": "Tee A.R., Anjum R., Blenis J. Inactivation of the Tuberous Sclerosis Complex-1 and-2 Gene Products Occurs by Phosphoinositide 3-Kinase/Akt-Dependent and-Independent Phosphorylation of Tuberin. J. Biol. Chem. 2003;278:37288\u201337296. doi: 10.1074/jbc.M303257200.", "ArticleIdList": ["10.1074/jbc.M303257200", "12867426"]}, {"Citation": "Kim S.G., Buel G.R., Blenis J. Nutrient Regulation of the MTOR Complex 1 Signaling Pathway. Mol. Cells. 2013;35:463\u2013473. doi: 10.1007/s10059-013-0138-2.", "ArticleIdList": ["10.1007/s10059-013-0138-2", "PMC3887879", "23694989"]}, {"Citation": "Avivar-Valderas A., Bobrovnikova-Marjon E., Alan Diehl J., Bardeesy N., Debnath J., Aguirre-Ghiso J.A. Regulation of Autophagy during ECM Detachment Is Linked to a Selective Inhibition of MTORC1 by PERK. Oncogene. 2013;32:4932\u20134940. doi: 10.1038/onc.2012.512.", "ArticleIdList": ["10.1038/onc.2012.512", "PMC3600386", "23160380"]}, {"Citation": "Ma X., Zhang S., He L., Rong Y., Brier L.W., Sun Q., Liu R., Fan W., Chen S., Yue Z. MTORC1-Mediated NRBF2 Phosphorylation Functions as a Switch for the Class III PtdIns3K and Autophagy. Autophagy. 2017;13:592\u2013607. doi: 10.1080/15548627.2016.1269988.", "ArticleIdList": ["10.1080/15548627.2016.1269988", "PMC5361594", "28059666"]}, {"Citation": "Yuan H.-X., Russell R.C., Guan K.-L. Regulation of PIK3C3/VPS34 Complexes by MTOR in Nutrient Stress-Induced Autophagy. Autophagy. 2013;9:1983\u20131995. doi: 10.4161/auto.26058.", "ArticleIdList": ["10.4161/auto.26058", "PMC4028342", "24013218"]}, {"Citation": "Martina J.A., Chen Y., Gucek M., Puertollano R. MTORC1 Functions as a Transcriptional Regulator of Autophagy by Preventing Nuclear Transport of TFEB. Autophagy. 2012;8:903\u2013914. doi: 10.4161/auto.19653.", "ArticleIdList": ["10.4161/auto.19653", "PMC3427256", "22576015"]}, {"Citation": "Yamamoto H., Kakuta S., Watanabe T.M., Kitamura A., Sekito T., Kondo-Kakuta C., Ichikawa R., Kinjo M., Ohsumi Y. Atg9 Vesicles Are an Important Membrane Source during Early Steps of Autophagosome Formation. J. Cell Biol. 2012;198:219\u2013233. doi: 10.1083/jcb.201202061.", "ArticleIdList": ["10.1083/jcb.201202061", "PMC3410421", "22826123"]}, {"Citation": "Kim J., Kundu M., Viollet B., Guan K.-L. AMPK and MTOR Regulate Autophagy through Direct Phosphorylation of Ulk1. Nat. Cell Biol. 2011;13:132\u2013141. doi: 10.1038/ncb2152.", "ArticleIdList": ["10.1038/ncb2152", "PMC3987946", "21258367"]}, {"Citation": "Perera R.M., Zoncu R. The Lysosome as a Regulatory Hub. Annu. Rev. Cell Dev. Biol. 2016;32:223\u2013253. doi: 10.1146/annurev-cellbio-111315-125125.", "ArticleIdList": ["10.1146/annurev-cellbio-111315-125125", "PMC9345128", "27501449"]}, {"Citation": "Saxton R.A., Sabatini D.M. MTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168:960\u2013976. doi: 10.1016/j.cell.2017.02.004.", "ArticleIdList": ["10.1016/j.cell.2017.02.004", "PMC5394987", "28283069"]}, {"Citation": "Chung C.Y.-S., Shin H.R., Berdan C.A., Ford B., Ward C.C., Olzmann J.A., Zoncu R., Nomura D.K. Covalent Targeting of the Vacuolar H+-ATPase Activates Autophagy via MTORC1 Inhibition. Nat. Chem. Biol. 2019;15:776\u2013785. doi: 10.1038/s41589-019-0308-4.", "ArticleIdList": ["10.1038/s41589-019-0308-4", "PMC6641988", "31285595"]}, {"Citation": "Suk J., Kwak S.S., Lee J.H., Choi J.H., Lee S.-H., Lee D.H., Byun B., Lee G.-H., Joe C.O. Alkaline Stress-Induced Autophagy Is Mediated by MTORC1 Inactivation. J. Cell Biochem. 2011;112:2566\u20132573. doi: 10.1002/jcb.23181.", "ArticleIdList": ["10.1002/jcb.23181", "21590709"]}, {"Citation": "Cybulski N., Polak P., Auwerx J., R\u00fcegg M.A., Hall M.N. MTOR Complex 2 in Adipose Tissue Negatively Controls Whole-Body Growth. Proc. Natl. Acad. Sci. USA. 2009;106:9902\u20139907. doi: 10.1073/pnas.0811321106.", "ArticleIdList": ["10.1073/pnas.0811321106", "PMC2700987", "19497867"]}, {"Citation": "Kumar A., Harris T.E., Keller S.R., Choi K.M., Magnuson M.A., Lawrence J.C., Jr. Muscle-Specific Deletion of Rictor Impairs Insulin-Stimulated Glucose Transport and Enhances Basal Glycogen Synthase Activity. Mol. Cell Biol. 2008;28:61\u201370. doi: 10.1128/MCB.01405-07.", "ArticleIdList": ["10.1128/MCB.01405-07", "PMC2223287", "17967879"]}, {"Citation": "Zhang C., Wendel A.A., Keogh M.R., Harris T.E., Chen J., Coleman R.A. Glycerolipid Signals Alter MTOR Complex 2 (MTORC2) to Diminish Insulin Signaling. Proc. Natl. Acad. Sci. USA. 2012;109:1667\u20131672. doi: 10.1073/pnas.1110730109.", "ArticleIdList": ["10.1073/pnas.1110730109", "PMC3277174", "22307628"]}, {"Citation": "Morita M., Gravel S.-P., Hulea L., Larsson O., Pollak M., St-Pierre J., Topisirovic I. MTOR Coordinates Protein Synthesis, Mitochondrial Activity and Proliferation. Cell Cycle. 2015;14:473\u2013480. doi: 10.4161/15384101.2014.991572.", "ArticleIdList": ["10.4161/15384101.2014.991572", "PMC4615141", "25590164"]}, {"Citation": "Drummond M.J., Rasmussen B.B. Leucine-Enriched Nutrients and the Regulation of MTOR Signalling and Human Skeletal Muscle Protein Synthesis. Curr. Opin. Clin. Nutr. Metab. Care. 2008;11:222. doi: 10.1097/MCO.0b013e3282fa17fb.", "ArticleIdList": ["10.1097/MCO.0b013e3282fa17fb", "PMC5096790", "18403916"]}, {"Citation": "Conn C.S., Qian S.-B. MTOR Signaling in Protein Homeostasis: Less Is More? Cell Cycle. 2011;10:1940\u20131947. doi: 10.4161/cc.10.12.15858.", "ArticleIdList": ["10.4161/cc.10.12.15858", "PMC3154417", "21555915"]}, {"Citation": "Hayashi A.A., Proud C.G. The Rapid Activation of Protein Synthesis by Growth Hormone Requires Signaling through MTOR. Am. J. Physiol.-Endocrinol. Metab. 2007;292:E1647\u2013E1655. doi: 10.1152/ajpendo.00674.2006.", "ArticleIdList": ["10.1152/ajpendo.00674.2006", "17284572"]}, {"Citation": "Thoreen C.C. Many Roads from MTOR to EIF4F. Biochem. Soc. Trans. 2013;41:913\u2013916. doi: 10.1042/BST20130082.", "ArticleIdList": ["10.1042/BST20130082", "23863155"]}, {"Citation": "Miloslavski R., Cohen E., Avraham A., Iluz Y., Hayouka Z., Kasir J., Mudhasani R., Jones S.N., Cybulski N., R\u00fcegg M.A. Oxygen Sufficiency Controls TOP MRNA Translation via the TSC-Rheb-MTOR Pathway in a 4E-BP-Independent Manner. J. Mol. Cell Biol. 2014;6:255\u2013266. doi: 10.1093/jmcb/mju008.", "ArticleIdList": ["10.1093/jmcb/mju008", "PMC4034726", "24627160"]}, {"Citation": "Patursky-Polischuk I., Stolovich-Rain M., Hausner-Hanochi M., Kasir J., Cybulski N., Avruch J., R\u00fcegg M.A., Hall M.N., Meyuhas O. The TSC-MTOR Pathway Mediates Translational Activation of TOP MRNAs by Insulin Largely in a Raptor-or Rictor-Independent Manner. Mol. Cell Biol. 2009;29:640\u2013649. doi: 10.1128/MCB.00980-08.", "ArticleIdList": ["10.1128/MCB.00980-08", "PMC2630691", "19047368"]}, {"Citation": "Stolovich M., Tang H., Hornstein E., Levy G., Cohen R., Bae S.S., Birnbaum M.J., Meyuhas O. Transduction of Growth or Mitogenic Signals into Translational Activation of TOP MRNAs Is Fully Reliant on the Phosphatidylinositol 3-Kinase-Mediated Pathway but Requires Neither S6K1 nor RpS6 Phosphorylation. Mol. Cell Biol. 2002;22:8101\u20138113. doi: 10.1128/MCB.22.23.8101-8113.2002.", "ArticleIdList": ["10.1128/MCB.22.23.8101-8113.2002", "PMC134064", "12417714"]}, {"Citation": "Tang H., Hornstein E., Stolovich M., Levy G., Livingstone M., Templeton D., Avruch J., Meyuhas O. Amino Acid-Induced Translation of TOP MRNAs Is Fully Dependent on Phosphatidylinositol 3-Kinase-Mediated Signaling, Is Partially Inhibited by Rapamycin, and Is Independent of S6K1 and RpS6 Phosphorylation. Mol. Cell Biol. 2001;21:8671\u20138683. doi: 10.1128/MCB.21.24.8671-8683.2001.", "ArticleIdList": ["10.1128/MCB.21.24.8671-8683.2001", "PMC100027", "11713299"]}, {"Citation": "Musa J., Orth M.F., Dallmayer M., Baldauf M., Pardo C., Rotblat B., Kirchner T., Leprivier G., Gr\u00fcnewald T.G.P. Eukaryotic Initiation Factor 4E-Binding Protein 1 (4E-BP1): A Master Regulator of MRNA Translation Involved in Tumorigenesis. Oncogene. 2016;35:4675\u20134688. doi: 10.1038/onc.2015.515.", "ArticleIdList": ["10.1038/onc.2015.515", "26829052"]}, {"Citation": "Mamane Y., Petroulakis E., Martineau Y., Sato T.-A., Larsson O., Rajasekhar V.K., Sonenberg N. Epigenetic Activation of a Subset of MRNAs by EIF4E Explains Its Effects on Cell Proliferation. PLoS ONE. 2007;2:e242. doi: 10.1371/journal.pone.0000242.", "ArticleIdList": ["10.1371/journal.pone.0000242", "PMC1797416", "17311107"]}, {"Citation": "Eliseeva I., Vasilieva M., Ovchinnikov L.P. Translation of Human \u03b2-Actin MRNA Is Regulated by MTOR Pathway. Genes. 2019;10:96. doi: 10.3390/genes10020096.", "ArticleIdList": ["10.3390/genes10020096", "PMC6410274", "30700035"]}, {"Citation": "Sonenberg N., Hinnebusch A.G. Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets. Cell. 2009;136:731\u2013745. doi: 10.1016/j.cell.2009.01.042.", "ArticleIdList": ["10.1016/j.cell.2009.01.042", "PMC3610329", "19239892"]}, {"Citation": "Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., Bar-Peled L., Sabatini D.M. The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to MTORC1. Science. 2008;320:1496\u20131501. doi: 10.1126/science.1157535.", "ArticleIdList": ["10.1126/science.1157535", "PMC2475333", "18497260"]}, {"Citation": "Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D. Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling through MTOR and S6K1. Science. 2013;339:1323\u20131328. doi: 10.1126/science.1228792.", "ArticleIdList": ["10.1126/science.1228792", "PMC3753690", "23429703"]}, {"Citation": "Mayer C., Grummt I. Ribosome Biogenesis and Cell Growth: MTOR Coordinates Transcription by All Three Classes of Nuclear RNA Polymerases. Oncogene. 2006;25:6384\u20136391. doi: 10.1038/sj.onc.1209883.", "ArticleIdList": ["10.1038/sj.onc.1209883", "17041624"]}, {"Citation": "Mayer C., Zhao J., Yuan X., Grummt I. MTOR-Dependent Activation of the Transcription Factor TIF-IA Links RRNA Synthesis to Nutrient Availability. Genes Dev. 2004;18:423\u2013434. doi: 10.1101/gad.285504.", "ArticleIdList": ["10.1101/gad.285504", "PMC359396", "15004009"]}, {"Citation": "He J., Yang Y., Zhang J., Chen J., Wei X., He J., Luo L. Ribosome Biogenesis Protein Urb1 Acts Downstream of MTOR Complex 1 to Modulate Digestive Organ Development in Zebrafish. J. Genet. Genom. 2017;44:567\u2013576. doi: 10.1016/j.jgg.2017.09.013.", "ArticleIdList": ["10.1016/j.jgg.2017.09.013", "29246861"]}, {"Citation": "Binal Z., A\u00e7\u0131kg\u00f6z E., K\u0131z\u0131lay F., \u00d6ktem G., Altay B. Cross-Talk between Ribosome Biogenesis, Translation, and MTOR in CD133+ 4/CD44+ Prostate Cancer Stem Cells. Clin. Transl. Oncol. 2020;22:1040\u20131048. doi: 10.1007/s12094-019-02229-1.", "ArticleIdList": ["10.1007/s12094-019-02229-1", "31630355"]}, {"Citation": "Kazyken D., Kaz Y., Kiyan V., Zhylkibayev A.A., Chen C.-H., Agarwal N.K., Sarbassov D.D. The Nuclear Import of Ribosomal Proteins Is Regulated by MTOR. Oncotarget. 2014;5:9577. doi: 10.18632/oncotarget.2473.", "ArticleIdList": ["10.18632/oncotarget.2473", "PMC4259421", "25294810"]}, {"Citation": "Ping W., Liu X., Lei D., Zhang X. MTOR Signaling-Related MicroRNAs and Cancer Involvement. J. Cancer. 2018;9:667.", "ArticleIdList": ["PMC5858488", "29556324"]}, {"Citation": "Feng Z., Zhang H., Levine A.J., Jin S. The Coordinate Regulation of the P53 and MTOR Pathways in Cells. Proc. Natl. Acad. Sci. USA. 2005;102:8204\u20138209. doi: 10.1073/pnas.0502857102.", "ArticleIdList": ["10.1073/pnas.0502857102", "PMC1142118", "15928081"]}, {"Citation": "Vogelstein B., Lane D., Levine A.J. Surfing the P53 Network. Nature. 2000;408:307\u2013310. doi: 10.1038/35042675.", "ArticleIdList": ["10.1038/35042675", "11099028"]}, {"Citation": "Feng Z., Hu W., De Stanchina E., Teresky A.K., Jin S., Lowe S., Levine A.J. The Regulation of AMPK \u03921, TSC2, and PTEN Expression by P53: Stress, Cell and Tissue Specificity, and the Role of These Gene Products in Modulating the IGF-1-AKT-MTOR Pathways. Cancer Res. 2007;67:3043\u20133053. doi: 10.1158/0008-5472.CAN-06-4149.", "ArticleIdList": ["10.1158/0008-5472.CAN-06-4149", "17409411"]}, {"Citation": "Sun Q., Chen X., Ma J., Peng H., Wang F., Zha X., Wang Y., Jing Y., Yang H., Chen R. Mammalian Target of Rapamycin Up-Regulation of Pyruvate Kinase Isoenzyme Type M2 Is Critical for Aerobic Glycolysis and Tumor Growth. Proc. Natl. Acad. Sci. USA. 2011;108:4129\u20134134. doi: 10.1073/pnas.1014769108.", "ArticleIdList": ["10.1073/pnas.1014769108", "PMC3054028", "21325052"]}, {"Citation": "Chiang G.G., Abraham R.T. Targeting the MTOR Signaling Network in Cancer. Trends Mol. Med. 2007;13:433\u2013442. doi: 10.1016/j.molmed.2007.08.001.", "ArticleIdList": ["10.1016/j.molmed.2007.08.001", "17905659"]}, {"Citation": "Jhanwar-Uniyal M., Jeevan D., Neil J., Shannon C., Albert L., Murali R. Deconstructing MTOR Complexes in Regulation of Glioblastoma Multiforme and Its Stem Cells. Adv. Biol. Regul. 2013;53:202\u2013210. doi: 10.1016/j.jbior.2012.10.001.", "ArticleIdList": ["10.1016/j.jbior.2012.10.001", "23231881"]}, {"Citation": "Nagahashi M., Hait N.C., Maceyka M., Avni D., Takabe K., Milstien S., Spiegel S. Sphingosine-1-Phosphate in Chronic Intestinal Inflammation and Cancer. Adv. Biol. Regul. 2014;54:112\u2013120. doi: 10.1016/j.jbior.2013.10.001.", "ArticleIdList": ["10.1016/j.jbior.2013.10.001", "PMC3946530", "24210073"]}, {"Citation": "Pyne N.J., Ohotski J., Bittman R., Pyne S. The Role of Sphingosine 1-Phosphate in Inflammation and Cancer. Adv. Biol. Regul. 2014;54:121\u2013129. doi: 10.1016/j.jbior.2013.08.005.", "ArticleIdList": ["10.1016/j.jbior.2013.08.005", "24070975"]}, {"Citation": "Pyne N.J., Tonelli F., Lim K.G., Long J., Edwards J., Pyne S. Targeting Sphingosine Kinase 1 in Cancer. Adv. Biol. Regul. 2012;52:31\u201338. doi: 10.1016/j.advenzreg.2011.07.001.", "ArticleIdList": ["10.1016/j.advenzreg.2011.07.001", "21791223"]}, {"Citation": "Liu L., Li F., Cardelli J.A., Martin K.A., Blenis J., Huang S. Rapamycin Inhibits Cell Motility by Suppression of MTOR-Mediated S6K1 and 4E-BP1 Pathways. Oncogene. 2006;25:7029\u20137040. doi: 10.1038/sj.onc.1209691.", "ArticleIdList": ["10.1038/sj.onc.1209691", "16715128"]}, {"Citation": "Vivanco I., Sawyers C.L. The Phosphatidylinositol 3-Kinase\u2013AKT Pathway in Human Cancer. Nat. Rev. Cancer. 2002;2:489\u2013501. doi: 10.1038/nrc839.", "ArticleIdList": ["10.1038/nrc839", "12094235"]}, {"Citation": "Sansal I., Sellers W.R. The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway. J. Clin. Oncol. 2004;22:2954\u20132963. doi: 10.1200/JCO.2004.02.141.", "ArticleIdList": ["10.1200/JCO.2004.02.141", "15254063"]}, {"Citation": "Stiles B., Groszer M., Wang S., Jiao J., Wu H. PTENless Means More. Dev. Biol. 2004;273:175\u2013184. doi: 10.1016/j.ydbio.2004.06.008.", "ArticleIdList": ["10.1016/j.ydbio.2004.06.008", "15328005"]}, {"Citation": "Wymann M.P., Zvelebil M., Laffargue M. Phosphoinositide 3-Kinase Signalling\u2013Which Way to Target? Trends Pharmacol. Sci. 2003;24:366\u2013376. doi: 10.1016/S0165-6147(03)00163-9.", "ArticleIdList": ["10.1016/S0165-6147(03)00163-9", "12871670"]}, {"Citation": "Menon S., Manning B.D. Common Corruption of the MTOR Signaling Network in Human Tumors. Oncogene. 2008;27:S43\u2013S51. doi: 10.1038/onc.2009.352.", "ArticleIdList": ["10.1038/onc.2009.352", "PMC3752670", "19956179"]}, {"Citation": "Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and Functional Inactivation of TSC2 by Erk: Implications for Tuberous Sclerosisand Cancer Pathogenesis. Cell. 2005;121:179\u2013193. doi: 10.1016/j.cell.2005.02.031.", "ArticleIdList": ["10.1016/j.cell.2005.02.031", "15851026"]}, {"Citation": "Potter C.J., Pedraza L.G., Xu T. Akt Regulates Growth by Directly Phosphorylating Tsc2. Nat. Cell Biol. 2002;4:658\u2013665. doi: 10.1038/ncb840.", "ArticleIdList": ["10.1038/ncb840", "12172554"]}, {"Citation": "Lee D.-F., Kuo H.-P., Chen C.-T., Hsu J.-M., Chou C.-K., Wei Y., Sun H.-L., Li L.-Y., Ping B., Huang W.-C. IKK\u03b2 Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the MTOR Pathway. Cell. 2007;130:440\u2013455. doi: 10.1016/j.cell.2007.05.058.", "ArticleIdList": ["10.1016/j.cell.2007.05.058", "17693255"]}, {"Citation": "Li Y., Inoki K., Vacratsis P., Guan K.-L. The P38 and MK2 Kinase Cascade Phosphorylates Tuberin, the Tuberous Sclerosis 2 Gene Product, and Enhances Its Interaction with 14-3-3. J. Biol. Chem. 2003;278:13663\u201313671. doi: 10.1074/jbc.M300862200.", "ArticleIdList": ["10.1074/jbc.M300862200", "12582162"]}, {"Citation": "Dalle Pezze P., Ruf S., Sonntag A.G., Langelaar-Makkinje M., Hall P., Heberle A.M., Razquin Navas P., Van Eunen K., T\u00f6lle R.C., Schwarz J.J. A Systems Study Reveals Concurrent Activation of AMPK and MTOR by Amino Acids. Nat. Commun. 2016;7:1\u201319. doi: 10.1038/ncomms13254.", "ArticleIdList": ["10.1038/ncomms13254", "PMC5121333", "27869123"]}, {"Citation": "Efeyan A., Zoncu R., Chang S., Gumper I., Snitkin H., Wolfson R.L., Kirak O., Sabatini D.D., Sabatini D.M. Regulation of MTORC1 by the Rag GTPases Is Necessary for Neonatal Autophagy and Survival. Nature. 2013;493:679\u2013683. doi: 10.1038/nature11745.", "ArticleIdList": ["10.1038/nature11745", "PMC4000705", "23263183"]}, {"Citation": "Ghislat G., Patron M., Rizzuto R., Knecht E. Withdrawal of Essential Amino Acids Increases Autophagy by a Pathway Involving Ca2+/Calmodulin-Dependent Kinase Kinase-\u03b2 (CaMKK-\u03b2) J. Biol. Chem. 2012;287:38625\u201338636. doi: 10.1074/jbc.M112.365767.", "ArticleIdList": ["10.1074/jbc.M112.365767", "PMC3493907", "23027865"]}, {"Citation": "Andjelkovic M., Alessi D.R., Meier R., Fernandez A., Lamb N.J., Frech M., Cron P., Cohen P., Lucocq J.M., Hemmings B.A. Role of Translocation in the Activation and Function of Protein Kinase B. J. Biol. Chem. 1997;272:31515\u201331524. doi: 10.1074/jbc.272.50.31515.", "ArticleIdList": ["10.1074/jbc.272.50.31515", "9395488"]}, {"Citation": "Frech M., Andjelkovic M., Ingley E., Reddy K.K., Falck J.R., Hemmings B.A. High Affinity Binding of Inositol Phosphates and Phosphoinositides to the Pleckstrin Homology Domain of RAC/Protein Kinase B and Their Influence on Kinase Activity. J. Biol. Chem. 1997;272:8474\u20138481. doi: 10.1074/jbc.272.13.8474.", "ArticleIdList": ["10.1074/jbc.272.13.8474", "9079675"]}, {"Citation": "Ma X.M., Blenis J. Molecular Mechanisms of MTOR-Mediated Translational Control. Nat. Rev. Mol. Cell Biol. 2009;10:307\u2013318. doi: 10.1038/nrm2672.", "ArticleIdList": ["10.1038/nrm2672", "19339977"]}, {"Citation": "Brunn G.J., Hudson C.C., Sekulic A., Williams J.M., Hosoi H., Houghton P.J., Lawrence J.C., Jr., Abraham R.T. Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin. Science. 1997;277:99\u2013101. doi: 10.1126/science.277.5322.99.", "ArticleIdList": ["10.1126/science.277.5322.99", "9204908"]}, {"Citation": "Hara K., Yonezawa K., Kozlowski M.T., Sugimoto T., Andrabi K., Weng Q.-P., Kasuga M., Nishimoto I., Avruch J. Regulation of EIF-4E BP1 Phosphorylation by MTOR. J. Biol. Chem. 1997;272:26457\u201326463. doi: 10.1074/jbc.272.42.26457.", "ArticleIdList": ["10.1074/jbc.272.42.26457", "9334222"]}, {"Citation": "Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., Griffiths J.R., Chung Y.-L., Schulze A. SREBP Activity Is Regulated by MTORC1 and Contributes to Akt-Dependent Cell Growth. Cell Metab. 2008;8:224\u2013236. doi: 10.1016/j.cmet.2008.07.007.", "ArticleIdList": ["10.1016/j.cmet.2008.07.007", "PMC2593919", "18762023"]}, {"Citation": "Castilho R.M., Squarize C.H., Chodosh L.A., Williams B.O., Gutkind J.S. MTOR Mediates Wnt-Induced Epidermal Stem Cell Exhaustion and Aging. Cell Stem Cell. 2009;5:279\u2013289. doi: 10.1016/j.stem.2009.06.017.", "ArticleIdList": ["10.1016/j.stem.2009.06.017", "PMC2939833", "19733540"]}, {"Citation": "Laplante M., Sabatini D.M. An Emerging Role of MTOR in Lipid Biosynthesis. Curr. Biol. 2009;19:R1046\u2013R1052. doi: 10.1016/j.cub.2009.09.058.", "ArticleIdList": ["10.1016/j.cub.2009.09.058", "PMC3390254", "19948145"]}, {"Citation": "Zoncu R., Efeyan A., Sabatini D.M. MTOR: From Growth Signal Integration to Cancer, Diabetes and Ageing. Nat. Rev. Mol. Cell Biol. 2011;12:21\u201335. doi: 10.1038/nrm3025.", "ArticleIdList": ["10.1038/nrm3025", "PMC3390257", "21157483"]}, {"Citation": "Burnett P.E., Barrow R.K., Cohen N.A., Snyder S.H., Sabatini D.M. RAFT1 Phosphorylation of the Translational Regulators P70 S6 Kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA. 1998;95:1432\u20131437. doi: 10.1073/pnas.95.4.1432.", "ArticleIdList": ["10.1073/pnas.95.4.1432", "PMC19032", "9465032"]}, {"Citation": "Brown E.J., Beal P.A., Keith C.T., Chen J., Bum Shin T., Schreiber S.L. Control of P70 S6 Kinase by Kinase Activity of FRAP in Vivo. Nature. 1995;377:441\u2013446. doi: 10.1038/377441a0.", "ArticleIdList": ["10.1038/377441a0", "7566123"]}, {"Citation": "Gingras A.-C., Raught B., Sonenberg N. EIF4 Initiation Factors: Effectors of MRNA Recruitment to Ribosomes and Regulators of Translation. Annu. Rev. Biochem. 1999;68:913\u2013963. doi: 10.1146/annurev.biochem.68.1.913.", "ArticleIdList": ["10.1146/annurev.biochem.68.1.913", "10872469"]}, {"Citation": "Wang X., Beugnet A., Murakami M., Yamanaka S., Proud C.G. Distinct Signaling Events Downstream of MTOR Cooperate to Mediate the Effects of Amino Acids and Insulin on Initiation Factor 4E-Binding Proteins. Mol. Cell Biol. 2005;25:2558\u20132572. doi: 10.1128/MCB.25.7.2558-2572.2005.", "ArticleIdList": ["10.1128/MCB.25.7.2558-2572.2005", "PMC1061630", "15767663"]}, {"Citation": "Yellen P., Saqcena M., Salloum D., Feng J., Preda A., Xu L., Rodrik-Outmezguine V., Foster D.A. High-Dose Rapamycin Induces Apoptosis in Human Cancer Cells by Dissociating MTOR Complex 1 and Suppressing Phosphorylation of 4E-BP1. Cell Cycle. 2011;10:3948\u20133956. doi: 10.4161/cc.10.22.18124.", "ArticleIdList": ["10.4161/cc.10.22.18124", "PMC3266120", "22071574"]}, {"Citation": "B\u00e4rlund M., Monni O., Kononen J., Cornelison R., Torhorst J., Sauter G., Kallioniemi O.-P., Kallioniemi A. Multiple Genes at 17q23 Undergo Amplification and Overexpression in Breast Cancer. Cancer Res. 2000;60:5340\u20135344.", "ArticleIdList": ["11034067"]}, {"Citation": "Surace E.I., Lusis E., Haipek C.A., Gutmann D.H. Functional Significance of S6K Overexpression in Meningioma Progression. Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc. 2004;56:295\u2013298. doi: 10.1002/ana.20201.", "ArticleIdList": ["10.1002/ana.20201", "15293284"]}, {"Citation": "Kim J.E., Chen J. Regulation of Peroxisome Proliferator\u2013Activated Receptor-\u03b3 Activity by Mammalian Target of Rapamycin and Amino Acids in Adipogenesis. Diabetes. 2004;53:2748\u20132756. doi: 10.2337/diabetes.53.11.2748.", "ArticleIdList": ["10.2337/diabetes.53.11.2748", "15504954"]}, {"Citation": "Armour S.M., Baur J.A., Hsieh S.N., Land-Bracha A., Thomas S.M., Sinclair D.A. Inhibition of Mammalian S6 Kinase by Resveratrol Suppresses Autophagy. Aging. 2009;1:515. doi: 10.18632/aging.100056.", "ArticleIdList": ["10.18632/aging.100056", "PMC2806030", "20157535"]}, {"Citation": "Fingar D.C., Salama S., Tsou C., Harlow E.D., Blenis J. Mammalian Cell Size Is Controlled by MTOR and Its Downstream Targets S6K1 and 4EBP1/EIF4E. Genes Dev. 2002;16:1472\u20131487. doi: 10.1101/gad.995802.", "ArticleIdList": ["10.1101/gad.995802", "PMC186342", "12080086"]}, {"Citation": "Wang J., Sheng Z., Cai Y. Effects of MicroRNA-513b on Cell Proliferation, Apoptosis, Invasion, and Migration by Targeting HMGB3 through Regulation of MTOR Signaling Pathway in Non-Small-Cell Lung Cancer. J. Cell Physiol. 2019;234:10934\u201310941. doi: 10.1002/jcp.27921.", "ArticleIdList": ["10.1002/jcp.27921", "30623409"]}, {"Citation": "Sun J., Chen Z., Tan X., Zhou F., Tan F., Gao Y., Sun N., Xu X., Shao K., He J. MicroRNA-99a/100 Promotes Apoptosis by Targeting MTOR in Human Esophageal Squamous Cell Carcinoma. Med. Oncol. 2013;30:1\u20139. doi: 10.1007/s12032-012-0411-9.", "ArticleIdList": ["10.1007/s12032-012-0411-9", "23292834"]}, {"Citation": "Liao W., Zhang Y. MicroRNA-381 Facilitates Autophagy and Apoptosis in Prostate Cancer Cells via Inhibiting the RELN-Mediated PI3K/AKT/MTOR Signaling Pathway. Life Sci. 2020;254:117672. doi: 10.1016/j.lfs.2020.117672.", "ArticleIdList": ["10.1016/j.lfs.2020.117672", "32304760"]}, {"Citation": "Liu T., Ye P., Ye Y., Han B. MicroRNA-216b Targets HK2 to Potentiate Autophagy and Apoptosis of Breast Cancer Cells via the MTOR Signaling Pathway. Int. J. Biol. Sci. 2021;17:2970. doi: 10.7150/ijbs.48933.", "ArticleIdList": ["10.7150/ijbs.48933", "PMC8326127", "34345220"]}, {"Citation": "Li X.J., Luo X.Q., Han B.W., Duan F.T., Wei P.P., Chen Y.Q. MicroRNA-100/99a, Deregulated in Acute Lymphoblastic Leukaemia, Suppress Proliferation and Promote Apoptosis by Regulating the FKBP51 and IGF1R/MTOR Signalling Pathways. Br. J. Cancer. 2013;109:2189\u20132198. doi: 10.1038/bjc.2013.562.", "ArticleIdList": ["10.1038/bjc.2013.562", "PMC3798962", "24030073"]}, {"Citation": "Ueng S.-H., Chen S.-C., Chang Y.-S., Hsueh S., Lin Y.-C., Chien H.-P., Lo Y.-F., Shen S.-C., Hsueh C. Phosphorylated MTOR Expression Correlates with Poor Outcome in Early-Stage Triple Negative Breast Carcinomas. Int. J. Clin. Exp. Pathol. 2012;5:806.", "ArticleIdList": ["PMC3466984", "23071863"]}, {"Citation": "Xu K., Liu P., Wei W. MTOR Signaling in Tumorigenesis. Biochim. Biophys. Acta BBA-Rev. Cancer. 2014;1846:638\u2013654. doi: 10.1016/j.bbcan.2014.10.007.", "ArticleIdList": ["10.1016/j.bbcan.2014.10.007", "PMC4261029", "25450580"]}, {"Citation": "Krieger K.L., Hu W.-F., Ripperger T., Woods N.T. Functional Impacts of the BRCA1-MTORC2 Interaction in Breast Cancer. Int. J. Mol. Sci. 2019;20:5876. doi: 10.3390/ijms20235876.", "ArticleIdList": ["10.3390/ijms20235876", "PMC6928641", "31771139"]}, {"Citation": "Woods N.T., Mesquita R.D., Sweet M., Carvalho M.A., Li X., Liu Y., Nguyen H., Thomas C.E., Iversen E.S., Jr., Marsillac S. Charting the Landscape of Tandem BRCT Domain\u2013Mediated Protein Interactions. Sci. Signal. 2012;5:rs6. doi: 10.1126/scisignal.2002255.", "ArticleIdList": ["10.1126/scisignal.2002255", "PMC4064718", "22990118"]}, {"Citation": "Wazir U., Newbold R.F., Jiang W.G., Sharma A.K., Mokbel K. Prognostic and Therapeutic Implications of MTORC1 and Rictor Expression in Human Breast Cancer. Oncol. Rep. 2013;29:1969\u20131974. doi: 10.3892/or.2013.2346.", "ArticleIdList": ["10.3892/or.2013.2346", "23503572"]}, {"Citation": "Dogan F., Avci C.B. Correlation between Telomerase and MTOR Pathway in Cancer Stem Cells. Gene. 2018;641:235\u2013239. doi: 10.1016/j.gene.2017.09.072.", "ArticleIdList": ["10.1016/j.gene.2017.09.072", "29074462"]}, {"Citation": "Hynes N.E., Boulay A. The MTOR Pathway in Breast Cancer. J. Mammary Gland Biol. Neoplasia. 2006;11:53\u201361. doi: 10.1007/s10911-006-9012-6.", "ArticleIdList": ["10.1007/s10911-006-9012-6", "16900391"]}, {"Citation": "McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Montalto G., Cervello M., Nicoletti F., Fagone P., Malaponte G., Mazzarino M.C. Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/MTOR Cascades Which Alter Therapy Response. Oncotarget. 2012;3:954. doi: 10.18632/oncotarget.652.", "ArticleIdList": ["10.18632/oncotarget.652", "PMC3660063", "23006971"]}, {"Citation": "Strimpakos A.S., Karapanagiotou E.M., Saif M.W., Syrigos K.N. The Role of MTOR in the Management of Solid Tumors: An Overview. Cancer Treat. Rev. 2009;35:148\u2013159. doi: 10.1016/j.ctrv.2008.09.006.", "ArticleIdList": ["10.1016/j.ctrv.2008.09.006", "19013721"]}, {"Citation": "Walsh S., Flanagan L., Quinn C., Evoy D., McDermott E.W., Pierce A., Duffy M.J. MTOR in Breast Cancer: Differential Expression in Triple-Negative and Non-Triple-Negative Tumors. Breast. 2012;21:178\u2013182. doi: 10.1016/j.breast.2011.09.008.", "ArticleIdList": ["10.1016/j.breast.2011.09.008", "21963359"]}, {"Citation": "Droog M., Beelen K., Linn S., Zwart W. Tamoxifen Resistance: From Bench to Bedside. Eur. J. Pharmacol. 2013;717:47\u201357. doi: 10.1016/j.ejphar.2012.11.071.", "ArticleIdList": ["10.1016/j.ejphar.2012.11.071", "23545365"]}, {"Citation": "Viedma-Rodr\u00edguez R., Baiza-Gutman L., Salamanca-G\u00f3mez F., Diaz-Zaragoza M., Mart\u00ednez-Hern\u00e1ndez G., Ruiz Esparza-Garrido R., Vel\u00e1zquez-Flores M.A., Arenas-Aranda D. Mechanisms Associated with Resistance to Tamoxifen in Estrogen Receptor-Positive Breast Cancer. Oncol. Rep. 2014;32:3\u201315. doi: 10.3892/or.2014.3190.", "ArticleIdList": ["10.3892/or.2014.3190", "24841429"]}, {"Citation": "Hare S.H., Harvey A.J. MTOR Function and Therapeutic Targeting in Breast Cancer. Am. J. Cancer Res. 2017;7:383.", "ArticleIdList": ["PMC5385631", "28400999"]}, {"Citation": "Iqbal N., Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol. Biol. Int. 2014;2014:1\u20139. doi: 10.1155/2014/852748.", "ArticleIdList": ["10.1155/2014/852748", "PMC4170925", "25276427"]}, {"Citation": "Brady S.W., Zhang J., Tsai M.-H., Yu D. PI3K-Independent MTOR Activation Promotes Lapatinib Resistance and IAP Expression That Can Be Effectively Reversed by MTOR and Hsp90 Inhibition. Cancer Biol. Ther. 2015;16:402\u2013411. doi: 10.1080/15384047.2014.1002693.", "ArticleIdList": ["10.1080/15384047.2014.1002693", "PMC4623386", "25692408"]}, {"Citation": "Margariti N., Fox S.B., Bottini A., Generali D. \u201cOvercoming Breast Cancer Drug Resistance with MTOR Inhibitors\u201d. Could It Be a Myth or a Real Possibility in the Short-Term Future? Breast Cancer Res. Treat. 2011;128:599\u2013606. doi: 10.1007/s10549-010-0986-9.", "ArticleIdList": ["10.1007/s10549-010-0986-9", "20945086"]}, {"Citation": "Liu Y., Mao C., Wang M., Liu N., Ouyang L., Liu S., Tang H., Cao Y., Liu S., Wang X. Cancer Progression Is Mediated by Proline Catabolism in Non-Small Cell Lung Cancer. Oncogene. 2020;39:2358\u20132376. doi: 10.1038/s41388-019-1151-5.", "ArticleIdList": ["10.1038/s41388-019-1151-5", "31911619"]}, {"Citation": "Schettino C., Bareschino M.A., Sacco P.C., Maione P., Rossi A., Casaluce F., Sgambato A., Gridelli C. New Molecular Targets in the Treatment of NSCLC. Curr. Pharm. Des. 2013;19:5333\u20135343. doi: 10.2174/13816128113199990343.", "ArticleIdList": ["10.2174/13816128113199990343", "23394083"]}, {"Citation": "Pothongsrisit S., Pongrakhananon V. Targeting the PI3K/AKT/MTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products. Molecules. 2021;26:4100.", "ArticleIdList": ["PMC8271933", "34279440"]}, {"Citation": "Ekman S., Wynes M.W., Hirsch F.R. The MTOR Pathway in Lung Cancer and Implications for Therapy and Biomarker Analysis. J. Thorac. Oncol. 2012;7:947\u2013953. doi: 10.1097/JTO.0b013e31825581bd.", "ArticleIdList": ["10.1097/JTO.0b013e31825581bd", "22588151"]}, {"Citation": "Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B. Somatic Mutations Affect Key Pathways in Lung Adenocarcinoma. Nature. 2008;455:1069\u20131075. doi: 10.1038/nature07423.", "ArticleIdList": ["10.1038/nature07423", "PMC2694412", "18948947"]}, {"Citation": "Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the Phosphoinositide 3-Kinase Pathway in Cancer. Nat. Rev. Drug Discov. 2009;8:627\u2013644. doi: 10.1038/nrd2926.", "ArticleIdList": ["10.1038/nrd2926", "PMC3142564", "19644473"]}, {"Citation": "Zhou W., Marcus A.I., Vertino P.M. Dysregulation of MTOR Activity through LKB1 Inactivation. Chin. J. Cancer. 2013;32:427. doi: 10.5732/cjc.013.10086.", "ArticleIdList": ["10.5732/cjc.013.10086", "PMC3845579", "23668926"]}, {"Citation": "Mamane Y., Petroulakis E., Rong L., Yoshida K., Ler L.W., Sonenberg N. EIF4E\u2013from Translation to Transformation. Oncogene. 2004;23:3172\u20133179. doi: 10.1038/sj.onc.1207549.", "ArticleIdList": ["10.1038/sj.onc.1207549", "15094766"]}, {"Citation": "Rosenwald I.B., Hutzler M.J., Wang S., Savas L., Fraire A.E. Expression of Eukaryotic Translation Initiation Factors 4E and 2\u03b1 Is Increased Frequently in Bronchioloalveolar but Not in Squamous Cell Carcinomas of the Lung. Cancer. 2001;92:2164\u20132171. doi: 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A.", "ArticleIdList": ["10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A", "11596034"]}, {"Citation": "Seki N., Takasu T., Mandai K., Nakata M., Saeki H., Heike Y., Takata I., Segawa Y., Hanafusa T., Eguchi K. Expression of Eukaryotic Initiation Factor 4E in Atypical Adenomatous Hyperplasia and Adenocarcinoma of the Human Peripheral Lung. Clin. Cancer Res. 2002;8:3046\u20133053.", "ArticleIdList": ["12374671"]}, {"Citation": "Frankel S.K., Moats-Staats B.M., Cool C.D., Wynes M.W., Stiles A.D., Riches D.W. Human Insulin-like Growth Factor-IA Expression in Transgenic Mice Promotes Adenomatous Hyperplasia but Not Pulmonary Fibrosis. Am. J. Physiol.-Lung Cell Mol. Physiol. 2005;288:L805\u2013L812. doi: 10.1152/ajplung.00420.2004.", "ArticleIdList": ["10.1152/ajplung.00420.2004", "15618451"]}, {"Citation": "Conde E., Angulo B., Tang M., Morente M., Torres-Lanzas J., Lopez-Encuentra A., Lopez-Rios F., Sanchez-Cespedes M. Molecular Context of the EGFR Mutations: Evidence for the Activation of MTOR/S6K Signaling. Clin. Cancer Res. 2006;12:710\u2013717. doi: 10.1158/1078-0432.CCR-05-1362.", "ArticleIdList": ["10.1158/1078-0432.CCR-05-1362", "16467080"]}, {"Citation": "Faoro L., Singleton P.A., Cervantes G.M., Lennon F.E., Choong N.W., Kanteti R., Ferguson B.D., Husain A.N., Tretiakova M.S., Ramnath N. EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation. J. Biol. Chem. 2010;285:18575\u201318585. doi: 10.1074/jbc.M109.075085.", "ArticleIdList": ["10.1074/jbc.M109.075085", "PMC2881783", "20360610"]}, {"Citation": "Dobashi Y., Suzuki S., Matsubara H., Kimura M., Endo S., Ooi A. Critical and Diverse Involvement of Akt/Mammalian Target of Rapamycin Signaling in Human Lung Carcinomas. Cancer. 2009;115:107\u2013118. doi: 10.1002/cncr.23996.", "ArticleIdList": ["10.1002/cncr.23996", "19090006"]}, {"Citation": "Wang H., Liu Y., Ding J., Huang Y., Liu J., Liu N., Ao Y., Hong Y., Wang L., Zhang L. Targeting MTOR Suppressed Colon Cancer Growth through 4EBP1/EIF4E/PUMA Pathway. Cancer Gene Ther. 2020;27:448\u2013460. doi: 10.1038/s41417-019-0117-7.", "ArticleIdList": ["10.1038/s41417-019-0117-7", "31257364"]}, {"Citation": "Francipane M.G., Lagasse E. MTOR Pathway in Colorectal Cancer: An Update. Oncotarget. 2014;5:49. doi: 10.18632/oncotarget.1548.", "ArticleIdList": ["10.18632/oncotarget.1548", "PMC3960188", "24393708"]}, {"Citation": "Gulhati P., Cai Q., Li J., Liu J., Rychahou P.G., Qiu S., Lee E.Y., Silva S.R., Bowen K.A., Gao T. Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal CancerTargeting MTOR Signaling in Colorectal Cancer. Clin. Cancer Res. 2009;15:7207\u20137216. doi: 10.1158/1078-0432.CCR-09-1249.", "ArticleIdList": ["10.1158/1078-0432.CCR-09-1249", "PMC2898570", "19934294"]}, {"Citation": "He K., Zheng X., Li M., Zhang L., Yu J. MTOR Inhibitors Induce Apoptosis in Colon Cancer Cells via CHOP-Dependent DR5 Induction on 4E-BP1 Dephosphorylation. Oncogene. 2016;35:148\u2013157. doi: 10.1038/onc.2015.79.", "ArticleIdList": ["10.1038/onc.2015.79", "PMC4603992", "25867072"]}, {"Citation": "Zhang Y.-J., Dai Q., Sun D.-F., Xiong H., Tian X.-Q., Gao F.-H., Xu M.-H., Chen G.-Q., Han Z.-G., Fang J.-Y. MTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer. Ann. Surg. Oncol. 2009;16:2617\u20132628. doi: 10.1245/s10434-009-0555-9.", "ArticleIdList": ["10.1245/s10434-009-0555-9", "19517193"]}, {"Citation": "Roulin D., Cerantola Y., Dormond-Meuwly A., Demartines N., Dormond O. Targeting MTORC2 Inhibits Colon Cancer Cell Proliferation in Vitro and Tumor Formation in Vivo. Mol. Cancer. 2010;9:1\u20134. doi: 10.1186/1476-4598-9-57.", "ArticleIdList": ["10.1186/1476-4598-9-57", "PMC2850884", "20226010"]}, {"Citation": "Gulhati P., Bowen K.A., Liu J., Stevens P.D., Rychahou P.G., Chen M., Lee E.Y., Weiss H.L., O\u2019Connor K.L., Gao T. MTORC1 and MTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling PathwaysmTOR Signaling in EMT and Metastasis of CRC. Cancer Res. 2011;71:3246\u20133256. doi: 10.1158/0008-5472.CAN-10-4058.", "ArticleIdList": ["10.1158/0008-5472.CAN-10-4058", "PMC3085654", "21430067"]}, {"Citation": "Aoki K., Tamai Y., Horiike S., Oshima M., Taketo M.M. Colonic Polyposis Caused by MTOR-Mediated Chromosomal Instability in Apc+/\u0394716 Cdx2+/- Compound Mutant Mice. Nat. Genet. 2003;35:323\u2013330. doi: 10.1038/ng1265.", "ArticleIdList": ["10.1038/ng1265", "14625550"]}, {"Citation": "Wang D., Xu C., Yang W., Chen J., Ou Y., Guan Y., Guan J., Liu Y. E3 Ligase RNF167 and Deubiquitinase STAMBPL1 Modulate MTOR and Cancer Progression. Mol. Cell. 2022;82:770\u2013784. doi: 10.1016/j.molcel.2022.01.002.", "ArticleIdList": ["10.1016/j.molcel.2022.01.002", "35114100"]}, {"Citation": "Weng M., Chen W., Chen X., Lu H., Sun Z., Yu Q., Sun P., Xu Y., Zhu M., Jiang N. Fasting Inhibits Aerobic Glycolysis and Proliferation in Colorectal Cancer via the Fdft1-Mediated AKT/MTOR/HIF1\u03b1 Pathway Suppression. Nat. Commun. 2020;11:1\u201317. doi: 10.1038/s41467-020-15795-8.", "ArticleIdList": ["10.1038/s41467-020-15795-8", "PMC7170903", "32313017"]}, {"Citation": "Wang K., Huang W., Sang X., Wu X., Shan Q., Tang D., Xu X., Cao G. Atractylenolide I Inhibits Colorectal Cancer Cell Proliferation by Affecting Metabolism and Stemness via AKT/MTOR Signaling. Phytomedicine. 2020;68:153191. doi: 10.1016/j.phymed.2020.153191.", "ArticleIdList": ["10.1016/j.phymed.2020.153191", "32135457"]}, {"Citation": "Roper J., Richardson M.P., Wang W.V., Richard L.G., Chen W., Coffee E.M., Sinnamon M.J., Lee L., Chen P.-C., Bronson R.T. The Dual PI3K/MTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer. PLoS ONE. 2011;6:e25132. doi: 10.1371/journal.pone.0025132.", "ArticleIdList": ["10.1371/journal.pone.0025132", "PMC3180374", "21966435"]}, {"Citation": "Belmont P.J., Jiang P., McKee T.D., Xie T., Isaacson J., Baryla N.E., Roper J., Sinnamon M.J., Lee N.V., Kan J.L. Resistance to Dual Blockade of the Kinases PI3K and MTOR in KRAS-Mutant Colorectal Cancer Models Results in Combined Sensitivity to Inhibition of the Receptor Tyrosine Kinase EGFR. Sci. Signal. 2014;7:ra107. doi: 10.1126/scisignal.2005516.", "ArticleIdList": ["10.1126/scisignal.2005516", "25389372"]}, {"Citation": "Shen J., Wang A., Wang Q., Gurvich I., Siegel A.B., Remotti H., Santella R.M. Exploration of Genome-Wide Circulating MicroRNA in Hepatocellular Carcinoma: MiR-483-5p as a Potential Biomarker. Cancer Epidemiol. Prev. Biomark. 2013;22:2364\u20132373. doi: 10.1158/1055-9965.EPI-13-0237.", "ArticleIdList": ["10.1158/1055-9965.EPI-13-0237", "PMC3963823", "24127413"]}, {"Citation": "Tan F.H., Bai Y., Saintigny P., Darido C. MTOR Signalling in Head and Neck Cancer: Heads Up. Cells. 2019;8:333. doi: 10.3390/cells8040333.", "ArticleIdList": ["10.3390/cells8040333", "PMC6523933", "30970654"]}, {"Citation": "Tian T., Li X., Zhang J. MTOR Signaling in Cancer and MTOR Inhibitors in Solid Tumor Targeting Therapy. Int. J. Mol. Sci. 2019;20:755. doi: 10.3390/ijms20030755.", "ArticleIdList": ["10.3390/ijms20030755", "PMC6387042", "30754640"]}, {"Citation": "Sun Z.-J., Zhang L., Hall B., Bian Y., Gutkind J.S., Kulkarni A.B. Chemopreventive and Chemotherapeutic Actions of MTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse ModelRapamycin Prevents Tumorigenesis in HNSCC Mouse Model. Clin. Cancer Res. 2012;18:5304\u20135313. doi: 10.1158/1078-0432.CCR-12-1371.", "ArticleIdList": ["10.1158/1078-0432.CCR-12-1371", "PMC3463723", "22859719"]}, {"Citation": "Moore E.C., Cash H.A., Caruso A.M., Uppaluri R., Hodge J.W., Van Waes C., Allen C.T. Enhanced Tumor Control with Combination MTOR and PD-L1 Inhibition in Syngeneic Oral Cavity CancersCombination MTOR and PD-L1 Checkpoint Inhibition. Cancer Immunol. Res. 2016;4:611\u2013620. doi: 10.1158/2326-6066.CIR-15-0252.", "ArticleIdList": ["10.1158/2326-6066.CIR-15-0252", "PMC4930724", "27076449"]}, {"Citation": "Bozec A., Ebran N., Radosevic-Robin N., Sudaka A., Monteverde M., Toussan N., Etienne-Grimaldi M.-C., Nigro C.L., Merlano M., Penault-Llorca F. Combination of m TOR and EGFR Targeting in an Orthotopic Xenograft Model of Head and Neck Cancer. Laryngoscope. 2016;126:E156\u2013E163. doi: 10.1002/lary.25754.", "ArticleIdList": ["10.1002/lary.25754", "26597440"]}, {"Citation": "Li Z., Yang Z., Passaniti A., Lapidus R.G., Liu X., Cullen K.J., Dan H.C. A Positive Feedback Loop Involving EGFR/Akt/MTORC1 and IKK/NF-\u039aB Regulates Head and Neck Squamous Cell Carcinoma Proliferation. Oncotarget. 2016;7:31892. doi: 10.18632/oncotarget.7441.", "ArticleIdList": ["10.18632/oncotarget.7441", "PMC5077984", "26895469"]}, {"Citation": "Suda T., Hama T., Kondo S., Yuza Y., Yoshikawa M., Urashima M., Kato T., Moriyama H. Copy Number Amplification of the PIK3CA Gene Is Associated with Poor Prognosis in Non-Lymph Node Metastatic Head and Neck Squamous Cell Carcinoma. BMC Cancer. 2012;12:1\u20139. doi: 10.1186/1471-2407-12-416.", "ArticleIdList": ["10.1186/1471-2407-12-416", "PMC3518180", "22994622"]}, {"Citation": "Keysar S.B., Le P.N., Miller B., Jackson B.C., Eagles J.R., Nieto C., Kim J., Tang B., Glogowska M.J., Morton J.J. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. J. Natl. Cancer Inst. 2017;109:djw189. doi: 10.1093/jnci/djw189.", "ArticleIdList": ["10.1093/jnci/djw189", "PMC5025278", "27634934"]}, {"Citation": "Pedrero J.M.G., Carracedo D.G., Pinto C.M., Zapatero A.H., Rodrigo J.P., Nieto C.S., Gonzalez M.V. Retracted: Frequent Genetic and Biochemical Alterations of the PI 3-K/AKT/PTEN Pathway in Head and Neck Squamous Cell Carcinoma. Int. J. Cancer. 2005;114:242\u2013248. doi: 10.1002/ijc.20711.", "ArticleIdList": ["10.1002/ijc.20711", "15543611"]}, {"Citation": "Georgy S.R., Cangkrama M., Srivastava S., Partridge D., Auden A., Dworkin S., McLean C.A., Jane S.M., Darido C. Identification of a Novel Proto-Oncogenic Network in Head and Neck Squamous Cell Carcinoma. JNCI J. Natl. Cancer Inst. 2015;107 doi: 10.1093/jnci/djv152.", "ArticleIdList": ["10.1093/jnci/djv152", "PMC4836819", "26063791"]}, {"Citation": "Bian Y., Hall B., Sun Z.-J., Molinolo A., Chen W., Gutkind J.S., Waes C.V., Kulkarni A.B. Loss of TGF-\u03b2 Signaling and PTEN Promotes Head and Neck Squamous Cell Carcinoma through Cellular Senescence Evasion and Cancer-Related Inflammation. Oncogene. 2012;31:3322\u20133332. doi: 10.1038/onc.2011.494.", "ArticleIdList": ["10.1038/onc.2011.494", "PMC3270146", "22037217"]}, {"Citation": "Kiaris H., Spandidos D.A., Jones A.S., Vaughan E.D., Field J.K. Mutations, Expression and Genomic Instability of the H-Ras Proto-Oncogene in Squamous Cell Carcinomas of the Head and Neck. Br. J. Cancer. 1995;72:123\u2013128. doi: 10.1038/bjc.1995.287.", "ArticleIdList": ["10.1038/bjc.1995.287", "PMC2034114", "7599040"]}, {"Citation": "Ruicci K.M., Pinto N., Khan M.I., Yoo J., Fung K., MacNeil D., Mymryk J.S., Barrett J.W., Nichols A.C. ERK-TSC2 Signalling in Constitutively-Active HRAS Mutant HNSCC Cells Promotes Resistance to PI3K Inhibition. Oral Oncol. 2018;84:95\u2013103. doi: 10.1016/j.oraloncology.2018.07.010.", "ArticleIdList": ["10.1016/j.oraloncology.2018.07.010", "30115483"]}, {"Citation": "Feng W., Duan X., Liu J., Xiao J., Brown R.E. Morphoproteomic Evidence of Constitutively Activated and Overexpressed MTOR Pathway in Cervical Squamous Carcinoma and High Grade Squamous Intraepithelial Lesions. Int. J. Clin. Exp. Pathol. 2009;2:249.", "ArticleIdList": ["PMC2600462", "19079619"]}, {"Citation": "Harada H., Andersen J.S., Mann M., Terada N., Korsmeyer S.J. P70S6 Kinase Signals Cell Survival as Well as Growth, Inactivating the pro-Apoptotic Molecule BAD. Proc. Natl. Acad. Sci. USA. 2001;98:9666\u20139670. doi: 10.1073/pnas.171301998.", "ArticleIdList": ["10.1073/pnas.171301998", "PMC55509", "11493700"]}, {"Citation": "Ji J., Zheng P.-S. Activation of MTOR Signaling Pathway Contributes to Survival of Cervical Cancer Cells. Gynecol. Oncol. 2010;117:103\u2013108. doi: 10.1016/j.ygyno.2009.12.020.", "ArticleIdList": ["10.1016/j.ygyno.2009.12.020", "20102778"]}, {"Citation": "Faried L.S., Faried A., Kanuma T., Sano T., Nakazato T., Tamura T., Kuwano H., Minegishi T. Predictive and Prognostic Role of Activated Mammalian Target of Rapamycin in Cervical Cancer Treated with Cisplatin-Based Neoadjuvant Chemotherapy. Oncol. Rep. 2006;16:57\u201363. doi: 10.3892/or.16.1.57.", "ArticleIdList": ["10.3892/or.16.1.57", "16786123"]}, {"Citation": "Wang F., Tan W.H., Liu W., Jin Y.X., Dong D.D., Zhao X.J., Liu Q. Effects of MiR-214 on Cervical Cancer Cell Proliferation, Apoptosis and Invasion via Modulating PI3K/AKT/MTOR Signal Pathway. Eur. Rev. Med. Pharmacol. Sci. 2018;22:1891\u20131898.", "ArticleIdList": ["29687840"]}, {"Citation": "Liu L., Wang Y., Geng C., Wang A., Han S., You X., Sun Y., Zhang J., Lu W., Zhang Y. CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/MTOR and NF-\u039aB Pathways. Front. Oncol. 2021:2153. doi: 10.3389/fonc.2021.655302.", "ArticleIdList": ["10.3389/fonc.2021.655302", "PMC8216081", "34164340"]}, {"Citation": "Deng J., Bai X., Feng X., Ni J., Beretov J., Graham P., Li Y. Inhibition of PI3K/Akt/MTOR Signaling Pathway Alleviates Ovarian Cancer Chemoresistance through Reversing Epithelial-Mesenchymal Transition and Decreasing Cancer Stem Cell Marker Expression. BMC Cancer. 2019;19:1\u201312. doi: 10.1186/s12885-019-5824-9.", "ArticleIdList": ["10.1186/s12885-019-5824-9", "PMC6591840", "31234823"]}, {"Citation": "Bi X., Lv X., Liu D., Guo H., Yao G., Wang L., Liang X., Yang Y. METTL3-Mediated Maturation of MiR-126-5p Promotes Ovarian Cancer Progression via PTEN-Mediated PI3K/Akt/MTOR Pathway. Cancer Gene Ther. 2021;28:335\u2013349. doi: 10.1038/s41417-020-00222-3.", "ArticleIdList": ["10.1038/s41417-020-00222-3", "32939058"]}, {"Citation": "Zhou Z., Tu Z., Zhang J., Shen X., Wan B., Li Y., Wang A., Zhao L., Hu J., Ma N. Follicular Fluid-Derived Exosomal MicroRNA-18b-5p Regulates PTEN-Mediated PI3K/Akt/MTOR Signaling Pathway to Inhibit Polycystic Ovary Syndrome Development. Mol. Neurobiol. 2022;59:2520\u20132531. doi: 10.1007/s12035-021-02714-1.", "ArticleIdList": ["10.1007/s12035-021-02714-1", "35092573"]}, {"Citation": "Chang L., Graham P.H., Hao J., Ni J., Bucci J., Cozzi P.J., Kearsley J.H., Li Y. Acquisition of Epithelial\u2013Mesenchymal Transition and Cancer Stem Cell Phenotypes Is Associated with Activation of the PI3K/Akt/MTOR Pathway in Prostate Cancer Radioresistance. Cell Death Dis. 2013;4:e875. doi: 10.1038/cddis.2013.407.", "ArticleIdList": ["10.1038/cddis.2013.407", "PMC3920940", "24157869"]}, {"Citation": "Shorning B.Y., Dass M.S., Smalley M.J., Pearson H.B. The PI3K-AKT-MTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int. J. Mol. Sci. 2020;21:4507. doi: 10.3390/ijms21124507.", "ArticleIdList": ["10.3390/ijms21124507", "PMC7350257", "32630372"]}, {"Citation": "Crumbaker M., Khoja L., Joshua A.M. AR Signaling and the PI3K Pathway in Prostate Cancer. Cancers. 2017;9:34. doi: 10.3390/cancers9040034.", "ArticleIdList": ["10.3390/cancers9040034", "PMC5406709", "28420128"]}, {"Citation": "Malik S.N., Brattain M., Ghosh P.M., Troyer D.A., Prihoda T., Bedolla R., Kreisberg J.I. Immunohistochemical Demonstration of Phospho-Akt in High Gleason Grade Prostate Cancer. Clin. Cancer Res. 2002;8:1168\u20131171.", "ArticleIdList": ["11948129"]}, {"Citation": "Bertoldo F., Silvestris F., Ibrahim T., Cognetti F., Generali D., Ripamonti C.I., Amadori D., Colleoni M.A., Conte P., Del Mastro L. Targeting Bone Metastatic Cancer: Role of the MTOR Pathway. Biochim. Biophys. Acta BBA\u2014Rev. Cancer. 2014;1845:248\u2013254. doi: 10.1016/j.bbcan.2014.01.009.", "ArticleIdList": ["10.1016/j.bbcan.2014.01.009", "24508774"]}, {"Citation": "Zhang J., Wang L., Wang H., Su Z., Pang X. Neuroinflammation and Central PI3K/Akt/MTOR Signal Pathway Contribute to Bone Cancer Pain. Mol. Pain. 2019;15:1744806919830240. doi: 10.1177/1744806919830240.", "ArticleIdList": ["10.1177/1744806919830240", "PMC6390230", "30717619"]}, {"Citation": "Ma J., Li M., Hock J., Yu X. Hyperactivation of MTOR Critically Regulates Abnormal Osteoclastogenesis in Neurofibromatosis Type 1. J. Orthop. Res. 2012;30:144\u2013152. doi: 10.1002/jor.21497.", "ArticleIdList": ["10.1002/jor.21497", "21748792"]}, {"Citation": "Ding L., Congwei L., Bei Q., Tao Y., Ruiguo W., Heze Y., Bo D., Zhihong L. MTOR: An Attractive Therapeutic Target for Osteosarcoma? Oncotarget. 2016;7:50805. doi: 10.18632/oncotarget.9305.", "ArticleIdList": ["10.18632/oncotarget.9305", "PMC5226621", "27177330"]}, {"Citation": "Martin D., Gutkind J.S. Human Tumor-Associated Viruses and New Insights into the Molecular Mechanisms of Cancer. Oncogene. 2008;27:S31\u2013S42. doi: 10.1038/onc.2009.351.", "ArticleIdList": ["10.1038/onc.2009.351", "19956178"]}, {"Citation": "Moore P.S., Chang Y. Why Do Viruses Cause Cancer? Highlights of the First Century of Human Tumour Virology. Nat. Rev. Cancer. 2010;10:878\u2013889. doi: 10.1038/nrc2961.", "ArticleIdList": ["10.1038/nrc2961", "PMC3718018", "21102637"]}, {"Citation": "Zhang L., Wu J., Ling M.T., Zhao L., Zhao K.-N. The Role of the PI3K/Akt/MTOR Signalling Pathway in Human Cancers Induced by Infection with Human Papillomaviruses. Mol. Cancer. 2015;14:1\u201313. doi: 10.1186/s12943-015-0361-x.", "ArticleIdList": ["10.1186/s12943-015-0361-x", "PMC4498560", "26022660"]}, {"Citation": "Sewell A., Brown B., Biktasova A., Mills G.B., Lu Y., Tyson D.R., Issaeva N., Yarbrough W.G. Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck CancerMutant PIK3CA in Head and Neck Cancer. Clin. Cancer Res. 2014;20:2300\u20132311. doi: 10.1158/1078-0432.CCR-13-2585.", "ArticleIdList": ["10.1158/1078-0432.CCR-13-2585", "PMC4027970", "24599934"]}, {"Citation": "Surviladze Z., Sterk R.T., DeHaro S.A., Ozbun M.A. Cellular Entry of Human Papillomavirus Type 16 Involves Activation of the Phosphatidylinositol 3-Kinase/Akt/MTOR Pathway and Inhibition of Autophagy. J. Virol. 2013;87:2508\u20132517. doi: 10.1128/JVI.02319-12.", "ArticleIdList": ["10.1128/JVI.02319-12", "PMC3571372", "23255786"]}, {"Citation": "Shrivastava S., Bhanja Chowdhury J., Steele R., Ray R., Ray R.B. Hepatitis C Virus Upregulates Beclin1 for Induction of Autophagy and Activates MTOR Signaling. J. Virol. 2012;86:8705\u20138712. doi: 10.1128/JVI.00616-12.", "ArticleIdList": ["10.1128/JVI.00616-12", "PMC3421755", "22674982"]}, {"Citation": "Aravinth S.P., Rajendran S., Li Y., Wu M., Wong A.H.Y., Schwarz H. Epstein\u2013Barr Virus-Encoded LMP1 Induces Ectopic CD137 Expression on Hodgkin and Reed\u2013Sternberg Cells via the PI3K-AKT-MTOR Pathway. Leuk. Lymphoma. 2019;60:2697\u20132704. doi: 10.1080/10428194.2019.1607330.", "ArticleIdList": ["10.1080/10428194.2019.1607330", "31058559"]}, {"Citation": "Wang W., Wen Q., Xu L., Xie G., Li J., Luo J., Chu S., Shi L., Huang D., Li J. Activation of Akt/MTOR Pathway Is Associated with Poor Prognosis of Nasopharyngeal Carcinoma. PLoS ONE. 2014;9:e106098. doi: 10.1371/journal.pone.0106098.", "ArticleIdList": ["10.1371/journal.pone.0106098", "PMC4148345", "25165983"]}, {"Citation": "Wang Y., Sun J., Yao N. Correlation of the AKT/MTOR Signaling Pathway with the Clinicopathological Features and Prognosis of Nasopharyngeal Carcinoma. Eur. J. Histochem. EJH. 2021;65:3304. doi: 10.4081/ejh.2021.3304.", "ArticleIdList": ["10.4081/ejh.2021.3304", "PMC8611413", "34783234"]}, {"Citation": "Zhang X., Wu Y., Sun X., Cui Q., Bai X., Dong G., Gao Z., Wang Y., Gao C., Sun S. The PI3K/AKT/MTOR Signaling Pathway Is Aberrantly Activated in Primary Central Nervous System Lymphoma and Correlated with a Poor Prognosis. BMC Cancer. 2022;22:1\u201311. doi: 10.1186/s12885-022-09275-z.", "ArticleIdList": ["10.1186/s12885-022-09275-z", "PMC8859899", "35184749"]}, {"Citation": "Bhatti M., Ippolito T., Mavis C., Gu J., Cairo M.S., Lim M.S., Hernandez-Ilizaliturri F., Barth M.J. Pre-Clinical Activity of Targeting the PI3K/Akt/MTOR Pathway in Burkitt Lymphoma. Oncotarget. 2018;9:21820. doi: 10.18632/oncotarget.25072.", "ArticleIdList": ["10.18632/oncotarget.25072", "PMC5955151", "29774105"]}, {"Citation": "Sindel A., McConnell I., Windle J., Sabo R., Chesney A., Lai G., Mauro A., Al-Juhaishi T., Rahmani M., Zweit J. Role of the PI3K Pathway in the Pathogenesis of Marginal Zone Lymphoma. Blood. 2018;132:4125. doi: 10.1182/blood-2018-99-111284.", "ArticleIdList": ["10.1182/blood-2018-99-111284"]}, {"Citation": "Okosun J., Wolfson R.L., Wang J., Araf S., Wilkins L., Castellano B.M., Escudero-Ibarz L., Al Seraihi A.F., Richter J., Bernhart S.H. Recurrent MTORC1-Activating RRAGC Mutations in Follicular Lymphoma. Nat. Genet. 2016;48:183\u2013188. doi: 10.1038/ng.3473.", "ArticleIdList": ["10.1038/ng.3473", "PMC4731318", "26691987"]}, {"Citation": "Yu D., Zhang Y., Chen G., Xie Y., Xu Z., Chang S., Hu L., Li B., Bu W., Wang Y. Targeting the PI3K/Akt/MTOR Signaling Pathway by Pterostilbene Attenuates Mantle Cell Lymphoma Progression. Acta Biochim. Biophys. Sin. 2018;50:782\u2013792. doi: 10.1093/abbs/gmy070.", "ArticleIdList": ["10.1093/abbs/gmy070", "29961897"]}, {"Citation": "Xia J., Guo S., Fang T., Feng D., Zhang X., Zhang Q., Liu J., Liu B., Li M., Zhu R. Dihydromyricetin Induces Autophagy in HepG2 Cells Involved in Inhibition of MTOR and Regulating Its Upstream Pathways. Food Chem. Toxicol. 2014;66:7\u201313. doi: 10.1016/j.fct.2014.01.014.", "ArticleIdList": ["10.1016/j.fct.2014.01.014", "24444546"]}, {"Citation": "Tsai J.-P., Lee C.-H., Ying T.-H., Lin C.-L., Lin C.-L., Hsueh J.-T., Hsieh Y.-H. Licochalcone A Induces Autophagy through PI3K/Akt/MTOR Inactivation and Autophagy Suppression Enhances Licochalcone A-Induced Apoptosis of Human Cervical Cancer Cells. Oncotarget. 2015;6:28851\u201328866. doi: 10.18632/oncotarget.4767.", "ArticleIdList": ["10.18632/oncotarget.4767", "PMC4745696", "26311737"]}, {"Citation": "Kumar S., Agnihotri N. Piperlongumine, a Piper Alkaloid Targets Ras/PI3K/Akt/MTOR Signaling Axis to Inhibit Tumor Cell Growth and Proliferation in DMH/DSS Induced Experimental Colon Cancer. Biomed. Pharmacother. 2019;109:1462\u20131477. doi: 10.1016/j.biopha.2018.10.182.", "ArticleIdList": ["10.1016/j.biopha.2018.10.182", "30551398"]}, {"Citation": "Acharya B., Chaijaroenkul W., Na-Bangchang K. Atractylodin Inhibited the Migration and Induced Autophagy in Cholangiocarcinoma Cells via PI3K/AKT/MTOR and P38MAPK Signalling Pathways. J. Pharm. Pharmacol. 2021;73:1191\u20131200. doi: 10.1093/jpp/rgab036.", "ArticleIdList": ["10.1093/jpp/rgab036", "33885818"]}, {"Citation": "Chen T., Hao J., He J., Zhang J., Li Y., Liu R., Li L. Cannabisin B Induces Autophagic Cell Death by Inhibiting the AKT/MTOR Pathway and S Phase Cell Cycle Arrest in HepG2 Cells. Food Chem. 2013;138:1034\u20131041. doi: 10.1016/j.foodchem.2012.11.102.", "ArticleIdList": ["10.1016/j.foodchem.2012.11.102", "23411211"]}, {"Citation": "Feng L.-M., Wang X.-F., Huang Q.-X. Thymoquinone Induces Cytotoxicity and Reprogramming of EMT in Gastric Cancer Cells by Targeting PI3K/Akt/MTOR Pathway. J. Biosci. 2017;42:547\u2013554. doi: 10.1007/s12038-017-9708-3.", "ArticleIdList": ["10.1007/s12038-017-9708-3", "29229873"]}, {"Citation": "Seo B.R., Min K.-J., Cho I.J., Kim S.C., Kwon T.K. Curcumin Significantly Enhances Dual PI3K/Akt and MTOR Inhibitor NVP-BEZ235-Induced Apoptosis in Human Renal Carcinoma Caki Cells through down-Regulation of P53-Dependent Bcl-2 Expression and Inhibition of Mcl-1 Protein Stability. PLoS ONE. 2014;9:e95588. doi: 10.1371/journal.pone.0095588.", "ArticleIdList": ["10.1371/journal.pone.0095588", "PMC3990719", "24743574"]}, {"Citation": "Gu R., Zhang M., Meng H., Xu D., Xie Y. Gallic Acid Targets Acute Myeloid Leukemia via Akt/MTOR-Dependent Mitochondrial Respiration Inhibition. Biomed. Pharmacother. 2018;105:491\u2013497. doi: 10.1016/j.biopha.2018.05.158.", "ArticleIdList": ["10.1016/j.biopha.2018.05.158", "29883944"]}, {"Citation": "Liu Z., Antalek M., Nguyen L., Li X., Tian X., Le A., Zi X. The Effect of Gartanin, a Naturally- Occurring Xanthone in Mangosteen Juice, on the MTOR Pathway, Autophagy, Apoptosis and the Growth of Human Urinary Bladder Cancer Cell Lines. Nutr. Cancer. 2013;65:68\u201377. doi: 10.1080/01635581.2013.785011.", "ArticleIdList": ["10.1080/01635581.2013.785011", "PMC3671488", "23682785"]}, {"Citation": "Liu Z., Ha U.-S., Yu K., Wu C., Yokoyama N., Zi X. Kavalactone Yangonin Induces Autophagy and Sensitizes Bladder Cancer Cells to Flavokawain A and Docetaxel via Inhibition of the MTOR Pathway. J. Biomed. Res. 2017;31:408\u2013418. doi: 10.7555/JBR.31.20160160.", "ArticleIdList": ["10.7555/JBR.31.20160160", "PMC5706433", "28959001"]}, {"Citation": "Alayev A., Salamon R.S., Schwartz N.S., Berman A.Y., Wiener S.L., Holz M.K. Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer. J. Cell. Physiol. 2017;232:436\u2013446. doi: 10.1002/jcp.25443.", "ArticleIdList": ["10.1002/jcp.25443", "27225870"]}, {"Citation": "Zhou C., Ding J., Wu Y. Resveratrol Induces Apoptosis of Bladder Cancer Cells via MiR-21 Regulation of the Akt/Bcl-2 Signaling Pathway. Mol. Med. Rep. 2014;9:1467\u20131473. doi: 10.3892/mmr.2014.1950.", "ArticleIdList": ["10.3892/mmr.2014.1950", "24535223"]}, {"Citation": "He S.-Q., Gao M., Fu Y.-F., Zhang Y.-N. Glycyrrhizic Acid Inhibits Leukemia Cell Growth and Migration via Blocking AKT/MTOR/STAT3 Signaling. Int. J. Clin. Exp. Pathol. 2015;8:5175\u20135181.", "ArticleIdList": ["PMC4503086", "26191214"]}, {"Citation": "Liu J., Zheng L., Zhong J., Wu N., Liu G., Lin X. Oleanolic Acid Induces Protective Autophagy in Cancer Cells through the JNK and MTOR Pathways. Oncol. Rep. 2014;32:567\u2013572. doi: 10.3892/or.2014.3239.", "ArticleIdList": ["10.3892/or.2014.3239", "24912497"]}, {"Citation": "Ma R., Zhang Z., Xu J., Liang X., Zhao Q. Poricoic Acid A Induces Apoptosis and Autophagy in Ovarian Cancer via Modulating the MTOR/P70s6k Signaling Axis. Braz. J. Med. Biol. Res. 2021;54:e11183. doi: 10.1590/1414-431x2021e11183.", "ArticleIdList": ["10.1590/1414-431x2021e11183", "PMC8521541", "34669780"]}, {"Citation": "Hong P., Liu Q.-W., Xie Y., Zhang Q.-H., Liao L., He Q.-Y., Li B., Xu W.W. Echinatin Suppresses Esophageal Cancer Tumor Growth and Invasion through Inducing AKT/MTOR-Dependent Autophagy and Apoptosis. Cell Death Dis. 2020;11:1\u201313. doi: 10.1038/s41419-020-2730-7.", "ArticleIdList": ["10.1038/s41419-020-2730-7", "PMC7354992", "32655130"]}, {"Citation": "Li Y., Sun Q., Li H., Yang B., Wang M. Vitexin Suppresses Renal Cell Carcinoma by Regulating MTOR Pathways. Transl. Androl. Urol. 2020;9:1700\u20131711. doi: 10.21037/tau-20-1094.", "ArticleIdList": ["10.21037/tau-20-1094", "PMC7475661", "32944531"]}, {"Citation": "Zhang L., Chen C., Duanmu J., Wu Y., Tao J., Yang A., Yin X., Xiong B., Gu J., Li C., et al. Cryptotanshinone Inhibits the Growth and Invasion of Colon Cancer by Suppressing Inflammation and Tumor Angiogenesis through Modulating MMP/TIMP System, PI3K/Akt/MTOR Signaling and HIF-1alpha Nuclear Translocation. Int. Immunopharmacol. 2018;65:429\u2013437. doi: 10.1016/j.intimp.2018.10.035.", "ArticleIdList": ["10.1016/j.intimp.2018.10.035", "30388517"]}, {"Citation": "Yun S.-M., Jung J.H., Jeong S.-J., Sohn E.J., Kim B., Kim S.-H. Tanshinone IIA Induces Autophagic Cell Death via Activation of AMPK and ERK and Inhibition of MTOR and P70 S6K in KBM-5 Leukemia Cells. Phytother. Res. 2013;28:458\u2013464. doi: 10.1002/ptr.5015.", "ArticleIdList": ["10.1002/ptr.5015", "23813779"]}, {"Citation": "Yang L., Xie J., Almoallim H.S., Alharbi S.A., Chen Y. Tomentosin Inhibits Cell Proliferation and Induces Apoptosis in MOLT-4 Leukemia Cancer Cells through the Inhibition of MTOR/PI3K/Akt Signaling Pathway. J. Biochem. Mol. Toxicol. 2021;35:e22719. doi: 10.1002/jbt.22719.", "ArticleIdList": ["10.1002/jbt.22719", "33501684"]}, {"Citation": "Li C., Zhou Y., Cai Y., Shui C., Liu W., Wang X., Jiang J., Zeng D., Gui C., Sun R. Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells in Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (MTOR)/PI3K/AKT Signaling Pathway. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2019;25:5054. doi: 10.12659/MSM.915387.", "ArticleIdList": ["10.12659/MSM.915387", "PMC6637819", "31322140"]}, {"Citation": "Chen H., Tang X., Liu T., Jing L., Wu J. Zingiberene Inhibits in Vitro and in Vivo Human Colon Cancer Cell Growth via Autophagy Induction, Suppression of PI3K/AKT/MTOR Pathway and Caspase 2 Deactivation. J. Buon. 2019;24:1470\u20131475.", "ArticleIdList": ["31646793"]}, {"Citation": "Totiger T.M., Srinivasan S., Jala V.R., Lamichhane P., Dosch A.R., Gaidarski A.A., Joshi C., Rangappa S., Castellanos J., Vemula P.K. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/MTOR Pathway in Pancreatic CancerTargeting PI3K/AKT/MTOR Pathway in Pancreatic Cancer. Mol. Cancer Ther. 2019;18:301\u2013311. doi: 10.1158/1535-7163.MCT-18-0464.", "ArticleIdList": ["10.1158/1535-7163.MCT-18-0464", "PMC6363854", "30404927"]}, {"Citation": "Qu Z., Lin Y., Mok D.K.-W., Bian Q., Tai W.C.-S., Chen S. Arnicolide D Inhibits Triple Negative Breast Cancer Cell Proliferation by Suppression of Akt/MTOR and STAT3 Signaling Pathways. Int. J. Med. Sci. 2020;17:1482. doi: 10.7150/ijms.46925.", "ArticleIdList": ["10.7150/ijms.46925", "PMC7359397", "32669950"]}, {"Citation": "Park K.-R., Leem H.H., Kwon Y.-J., Kwon I.K., Hong J.T., Yun H.-M. Falcarindiol Stimulates Apoptotic and Autophagic Cell Death to Attenuate Cell Proliferation, Cell Division, and Metastasis through the PI3K/AKT/MTOR/P70S6K Pathway in Human Oral Squamous Cell Carcinomas. Am. J. Chin. Med. 2022;50:295\u2013311. doi: 10.1142/S0192415X22500112.", "ArticleIdList": ["10.1142/S0192415X22500112", "34931585"]}, {"Citation": "Roy G., Guan S., Liu H., Zhang L. Rotundic Acid Induces DNA Damage and Cell Death in Hepatocellular Carcinoma through AKT/MTOR and MAPK Pathways. Front. Oncol. 2019;9:545. doi: 10.3389/fonc.2019.00545.", "ArticleIdList": ["10.3389/fonc.2019.00545", "PMC6606729", "31293977"]}, {"Citation": "Wei J., Zhang X., Pan H., He S., Yuan B., Liu Q., Zhang J., Ding Y. Eupafolin Inhibits Breast Cancer Cell Proliferation and Induces Apoptosis by Inhibiting the PI3K/Akt/MTOR Pathway. Oncol. Lett. 2021;21:1\u20139. doi: 10.3892/ol.2021.12593.", "ArticleIdList": ["10.3892/ol.2021.12593", "PMC7933747", "33692864"]}, {"Citation": "Hu S., Yin J., Yan S., Hu P., Huang J., Zhang G., Wang F., Tong Q., Zhang Y. Chaetocochin J, an Epipolythiodioxopiperazine Alkaloid, Induces Apoptosis and Autophagy in Colorectal Cancer via AMPK and PI3K/AKT/MTOR Pathways. Bioorganic Chem. 2021;109:104693. doi: 10.1016/j.bioorg.2021.104693.", "ArticleIdList": ["10.1016/j.bioorg.2021.104693", "33609914"]}, {"Citation": "Zhang H., Yi J.-K., Huang H., Park S., Park S., Kwon W., Kim E., Jang S., Kim S.-Y., Choi S.-K. Rhein Suppresses Colorectal Cancer Cell Growth by Inhibiting the MTOR Pathway In Vitro and In Vivo. Cancers. 2021;13:2176. doi: 10.3390/cancers13092176.", "ArticleIdList": ["10.3390/cancers13092176", "PMC8125196", "33946531"]}, {"Citation": "Karbowniczek M., Spittle C.S., Morrison T., Wu H., Henske E.P. MTOR Is Activated in the Majority of Malignant Melanomas. J. Investig. Dermatol. 2008;128:980\u2013987. doi: 10.1038/sj.jid.5701074.", "ArticleIdList": ["10.1038/sj.jid.5701074", "17914450"]}, {"Citation": "Vera Aguilera J., Rao R.D., Allred J.B., Suman V.J., Windschitl H.E., Kaur J.S., Maples W.J., Lowe V.J., Creagan E.T., Erickson L.A. Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance) Oncologist. 2018;23:887-e94. doi: 10.1634/theoncologist.2018-0100.", "ArticleIdList": ["10.1634/theoncologist.2018-0100", "PMC6156180", "29666297"]}, {"Citation": "Si L., Xu X., Kong Y., Flaherty K.T., Chi Z., Cui C., Sheng X., Li S., Dai J., Yu W. Major Response to Everolimus in Melanoma with Acquired Imatinib Resistance. J. Clin. Oncol. 2012;30:e37\u2013e40. doi: 10.1200/JCO.2011.37.9644.", "ArticleIdList": ["10.1200/JCO.2011.37.9644", "22162580"]}, {"Citation": "Hainsworth J.D., Infante J.R., Spigel D.R., Peyton J.D., Thompson D.S., Lane C.M., Clark B.L., Rubin M.S., Trent D.F., Burris III H.A. Bevacizumab and Everolimus in the Treatment of Patients with Metastatic Melanoma: A Phase 2 Trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010;116:4122\u20134129. doi: 10.1002/cncr.25320.", "ArticleIdList": ["10.1002/cncr.25320", "20564157"]}, {"Citation": "Niessner H., Kosnopfel C., Sinnberg T., Beck D., Krieg K., Wanke I., Lasithiotakis K., Bonin M., Garbe C., Meier F. Combined Activity of Temozolomide and the MTOR Inhibitor Temsirolimus in Metastatic Melanoma Involves DKK1. Exp. Dermatol. 2017;26:598\u2013606. doi: 10.1111/exd.13372.", "ArticleIdList": ["10.1111/exd.13372", "28423208"]}, {"Citation": "Rangwala R., Chang Y.C., Hu J., Algazy K.M., Evans T.L., Fecher L.A., Schuchter L.M., Torigian D.A., Panosian J.T., Troxel A.B. Combined MTOR and Autophagy Inhibition: Phase I Trial of Hydroxychloroquine and Temsirolimus in Patients with Advanced Solid Tumors and Melanoma. Autophagy. 2014;10:1391\u20131402. doi: 10.4161/auto.29119.", "ArticleIdList": ["10.4161/auto.29119", "PMC4203516", "24991838"]}, {"Citation": "Kolev V.N., Wright Q.G., Vidal C.M., Ring J.E., Shapiro I.M., Ricono J., Weaver D.T., Padval M.V., Pachter J.A., Xu Q. PI3K/MTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells. Cancer Res. 2015;75:446\u2013455. doi: 10.1158/0008-5472.CAN-14-1223.", "ArticleIdList": ["10.1158/0008-5472.CAN-14-1223", "25432176"]}, {"Citation": "Strickland L.R., Pal H.C., Elmets C.A., Afaq F. Targeting Drivers of Melanoma with Synthetic Small Molecules and Phytochemicals. Cancer Lett. 2015;359:20\u201335. doi: 10.1016/j.canlet.2015.01.016.", "ArticleIdList": ["10.1016/j.canlet.2015.01.016", "PMC4599342", "25597784"]}, {"Citation": "Schadendorf D., Hauschild A. Melanoma\u2014The Run of Success Continues. Nat. Rev. Clin. Oncol. 2014;11:75\u201376. doi: 10.1038/nrclinonc.2013.246.", "ArticleIdList": ["10.1038/nrclinonc.2013.246", "24419300"]}, {"Citation": "Shao Z., Bao Q., Jiang F., Qian H., Fang Q., Hu X. VS-5584, a Novel PI3K-MTOR Dual Inhibitor, Inhibits Melanoma Cell Growth in Vitro and in Vivo. PLoS ONE. 2015;10:e0132655. doi: 10.1371/journal.pone.0132655.", "ArticleIdList": ["10.1371/journal.pone.0132655", "PMC4512677", "26204252"]}, {"Citation": "Webster R.M., Mentzer S.E. The Malignant Melanoma Landscape. Nat. Rev. Drug Discov. 2014;13:491. doi: 10.1038/nrd4326.", "ArticleIdList": ["10.1038/nrd4326", "24981356"]}, {"Citation": "Wang J., Yang Z., Wen J., Ma F., Wang F., Yu K., Tang M., Wu W., Dong Y., Cheng X. SKLB-M8 Induces Apoptosis through the AKT/MTOR Signaling Pathway in Melanoma Models and Inhibits Angiogenesis with Decrease of ERK1/2 Phosphorylation. J. Pharmacol. Sci. 2014:14077FP. doi: 10.1254/jphs.14077FP.", "ArticleIdList": ["10.1254/jphs.14077FP", "25341684"]}, {"Citation": "Head S.A., Shi W., Zhao L., Gorshkov K., Pasunooti K., Chen Y., Deng Z., Li R., Shim J.S., Tan W. Antifungal Drug Itraconazole Targets VDAC1 to Modulate the AMPK/MTOR Signaling Axis in Endothelial Cells. Proc. Natl. Acad. Sci. USA. 2015;112:E7276\u2013E7285. doi: 10.1073/pnas.1512867112.", "ArticleIdList": ["10.1073/pnas.1512867112", "PMC4703001", "26655341"]}, {"Citation": "Liang G., Liu M., Wang Q., Shen Y., Mei H., Li D., Liu W. Itraconazole Exerts Its Anti-Melanoma Effect by Suppressing Hedgehog, Wnt, and PI3K/MTOR Signaling Pathways. Oncotarget. 2017;8:28510. doi: 10.18632/oncotarget.15324.", "ArticleIdList": ["10.18632/oncotarget.15324", "PMC5438669", "28212537"]}, {"Citation": "Oleksak P., Nepovimova E., Chrienova Z., Musilek K., Patocka J., Kuca K. Contemporary MTOR Inhibitor Scaffolds to Diseases Breakdown: A Patent Review (2015\u20132021) Eur. J. Med. Chem. 2022;238:114498. doi: 10.1016/j.ejmech.2022.114498.", "ArticleIdList": ["10.1016/j.ejmech.2022.114498", "35688004"]}, {"Citation": "Hua H., Kong Q., Zhang H., Wang J., Luo T., Jiang Y. Targeting MTOR for Cancer Therapy. J. Hematol. Oncol. 2019;12:1\u201319. doi: 10.1186/s13045-019-0754-1.", "ArticleIdList": ["10.1186/s13045-019-0754-1", "PMC6612215", "31277692"]}, {"Citation": "Xie J., Wang X., Proud C.G. MTOR Inhibitors in Cancer Therapy. F1000Research. 2016;5 doi: 10.12688/f1000research.9207.1.", "ArticleIdList": ["10.12688/f1000research.9207.1", "PMC5007757", "27635236"]}, {"Citation": "Xu X., Ye L., Araki K., Ahmed R. Seminars in Immunology. Volume 24. Elsevier; Amsterdam, The Netherlands: 2012. MTOR, Linking Metabolism and Immunity; pp. 429\u2013435.", "ArticleIdList": ["PMC3582734", "23352227"]}, {"Citation": "Zeng H. MTOR Signaling in Immune Cells and Its Implications for Cancer Immunotherapy. Cancer Lett. 2017;408:182\u2013189. doi: 10.1016/j.canlet.2017.08.038.", "ArticleIdList": ["10.1016/j.canlet.2017.08.038", "28888995"]}, {"Citation": "Pollizzi K.N., Patel C.H., Sun I.-H., Oh M.-H., Waickman A.T., Wen J., Delgoffe G.M., Powell J.D. MTORC1 and MTORC2 Selectively Regulate CD8+ T Cell Differentiation. J. Clin. Investig. 2015;125:2090\u20132108. doi: 10.1172/JCI77746.", "ArticleIdList": ["10.1172/JCI77746", "PMC4463194", "25893604"]}, {"Citation": "Yang K., Chi H. Seminars in Immunology. Volume 24. Elsevier; Amsterdam, The Netherlands: 2012. MTOR and Metabolic Pathways in T Cell Quiescence and Functional Activation; pp. 421\u2013428.", "ArticleIdList": ["PMC3855395", "23375549"]}, {"Citation": "Delgoffe G.M., Kole T.P., Zheng Y., Zarek P.E., Matthews K.L., Xiao B., Worley P.F., Kozma S.C., Powell J.D. The MTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment. Immunity. 2009;30:832\u2013844. doi: 10.1016/j.immuni.2009.04.014.", "ArticleIdList": ["10.1016/j.immuni.2009.04.014", "PMC2768135", "19538929"]}, {"Citation": "Delgoffe G.M., Pollizzi K.N., Waickman A.T., Heikamp E., Meyers D.J., Horton M.R., Xiao B., Worley P.F., Powell J.D. The Kinase MTOR Regulates the Differentiation of Helper T Cells through the Selective Activation of Signaling by MTORC1 and MTORC2. Nat. Immunol. 2011;12:295\u2013303. doi: 10.1038/ni.2005.", "ArticleIdList": ["10.1038/ni.2005", "PMC3077821", "21358638"]}, {"Citation": "Shi L.Z., Wang R., Huang G., Vogel P., Neale G., Green D.R., Chi H. HIF1\u03b1\u2013Dependent Glycolytic Pathway Orchestrates a Metabolic Checkpoint for the Differentiation of TH17 and Treg Cells. J. Exp. Med. 2011;208:1367\u20131376. doi: 10.1084/jem.20110278.", "ArticleIdList": ["10.1084/jem.20110278", "PMC3135370", "21708926"]}, {"Citation": "Wang R., Dillon C.P., Shi L.Z., Milasta S., Carter R., Finkelstein D., McCormick L.L., Fitzgerald P., Chi H., Munger J. The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte Activation. Immunity. 2011;35:871\u2013882. doi: 10.1016/j.immuni.2011.09.021.", "ArticleIdList": ["10.1016/j.immuni.2011.09.021", "PMC3248798", "22195744"]}, {"Citation": "Templeton A.J., Dutoit V., Cathomas R., Rothermundt C., B\u00e4rtschi D., Dr\u00f6ge C., Gautschi O., Borner M., Fechter E., Stenner F. Phase 2 Trial of Single-Agent Everolimus in Chemotherapy-Naive Patients with Castration-Resistant Prostate Cancer (SAKK 08/08) Eur. Urol. 2013;64:150\u2013158. doi: 10.1016/j.eururo.2013.03.040.", "ArticleIdList": ["10.1016/j.eururo.2013.03.040", "23582881"]}, {"Citation": "Kurebayashi Y., Nagai S., Ikejiri A., Ohtani M., Ichiyama K., Baba Y., Yamada T., Egami S., Hoshii T., Hirao A. PI3K-Akt-MTORC1-S6K1/2 Axis Controls Th17 Differentiation by Regulating Gfi1 Expression and Nuclear Translocation of ROR\u03b3. Cell Rep. 2012;1:360\u2013373. doi: 10.1016/j.celrep.2012.02.007.", "ArticleIdList": ["10.1016/j.celrep.2012.02.007", "22832227"]}, {"Citation": "Chapman N.M., Chi H. MTOR Signaling, Tregs and Immune Modulation. Immunotherapy. 2014;6:1295\u20131311. doi: 10.2217/imt.14.84.", "ArticleIdList": ["10.2217/imt.14.84", "PMC4291176", "25524385"]}, {"Citation": "Ouyang W., Beckett O., Ma Q., Paik J., DePinho R.A., Li M.O. Foxo Proteins Cooperatively Control the Differentiation of Foxp3+ Regulatory T Cells. Nat. Immunol. 2010;11:618\u2013627. doi: 10.1038/ni.1884.", "ArticleIdList": ["10.1038/ni.1884", "20467422"]}, {"Citation": "Huynh A., DuPage M., Priyadharshini B., Sage P.T., Quiros J., Borges C.M., Townamchai N., Gerriets V.A., Rathmell J.C., Sharpe A.H. Control of PI (3) Kinase in Treg Cells Maintains Homeostasis and Lineage Stability. Nat. Immunol. 2015;16:188\u2013196. doi: 10.1038/ni.3077.", "ArticleIdList": ["10.1038/ni.3077", "PMC4297515", "25559257"]}, {"Citation": "Shrestha S., Yang K., Guy C., Vogel P., Neale G., Chi H. Treg Cells Require the Phosphatase PTEN to Restrain TH1 and TFH Cell Responses. Nat. Immunol. 2015;16:178\u2013187. doi: 10.1038/ni.3076.", "ArticleIdList": ["10.1038/ni.3076", "PMC4297581", "25559258"]}, {"Citation": "Sun I.-H., Oh M.-H., Zhao L., Patel C.H., Arwood M.L., Xu W., Tam A.J., Blosser R.L., Wen J., Powell J.D. MTOR Complex 1 Signaling Regulates the Generation and Function of Central and Effector Foxp3+ Regulatory T Cells. J. Immunol. 2018;201:481\u2013492. doi: 10.4049/jimmunol.1701477.", "ArticleIdList": ["10.4049/jimmunol.1701477", "PMC6089237", "29884702"]}, {"Citation": "Pan Y., Yu Y., Wang X., Zhang T. Tumor-Associated Macrophages in Tumor Immunity. Front. Immunol. 2020;11:3151. doi: 10.3389/fimmu.2020.583084.", "ArticleIdList": ["10.3389/fimmu.2020.583084", "PMC7751482", "33365025"]}, {"Citation": "Zhang M., Liu F., Zhou P., Wang Q., Xu C., Li Y., Bian L., Liu Y., Zhou J., Wang F. The MTOR Signaling Pathway Regulates Macrophage Differentiation from Mouse Myeloid Progenitors by Inhibiting Autophagy. Autophagy. 2019;15:1150\u20131162. doi: 10.1080/15548627.2019.1578040.", "ArticleIdList": ["10.1080/15548627.2019.1578040", "PMC6613836", "30724690"]}, {"Citation": "Jiang H., Westerterp M., Wang C., Zhu Y., Ai D. Macrophage MTORC1 Disruption Reduces Inflammation and Insulin Resistance in Obese Mice. Diabetologia. 2014;57:2393\u20132404. doi: 10.1007/s00125-014-3350-5.", "ArticleIdList": ["10.1007/s00125-014-3350-5", "25120095"]}, {"Citation": "Mercalli A., Calavita I., Dugnani E., Citro A., Cantarelli E., Nano R., Melzi R., Maffi P., Secchi A., Sordi V. Rapamycin Unbalances the Polarization of Human Macrophages to M 1. Immunology. 2013;140:179\u2013190. doi: 10.1111/imm.12126.", "ArticleIdList": ["10.1111/imm.12126", "PMC3784164", "23710834"]}, {"Citation": "Byles V., Covarrubias A.J., Ben-Sahra I., Lamming D.W., Sabatini D.M., Manning B.D., Horng T. The TSC-MTOR Pathway Regulates Macrophage Polarization. Nat. Commun. 2013;4:1\u201311. doi: 10.1038/ncomms3834.", "ArticleIdList": ["10.1038/ncomms3834", "PMC3876736", "24280772"]}, {"Citation": "Gabrilovich D.I., Nagaraj S. Myeloid-Derived Suppressor Cells as Regulators of the Immune System. Nat. Rev. Immunol. 2009;9:162\u2013174. doi: 10.1038/nri2506.", "ArticleIdList": ["10.1038/nri2506", "PMC2828349", "19197294"]}, {"Citation": "Conciatori F., Bazzichetto C., Falcone I., Pilotto S., Bria E., Cognetti F., Milella M., Ciuffreda L. Role of MTOR Signaling in Tumor Microenvironment: An Overview. Int. J. Mol. Sci. 2018;19:2453. doi: 10.3390/ijms19082453.", "ArticleIdList": ["10.3390/ijms19082453", "PMC6121402", "30126252"]}, {"Citation": "Shrivastava R., Asif M., Singh V., Dubey P., Malik S.A., Tewari B.N., Baghel K.S., Pal S., Nagar G.K., Chattopadhyay N. M2 Polarization of Macrophages by Oncostatin M in Hypoxic Tumor Microenvironment Is Mediated by MTORC2 and Promotes Tumor Growth and Metastasis. Cytokine. 2019;118:130\u2013143. doi: 10.1016/j.cyto.2018.03.032.", "ArticleIdList": ["10.1016/j.cyto.2018.03.032", "29625858"]}, {"Citation": "Welte T., Kim I.S., Tian L., Gao X., Wang H., Li J., Holdman X.B., Herschkowitz J.I., Pond A., Xie G. Oncogenic MTOR Signalling Recruits Myeloid-Derived Suppressor Cells to Promote Tumour Initiation. Nat. Cell Biol. 2016;18:632\u2013644. doi: 10.1038/ncb3355.", "ArticleIdList": ["10.1038/ncb3355", "PMC4884142", "27183469"]}, {"Citation": "Ryzhov S.V., Pickup M.W., Chytil A., Gorska A.E., Zhang Q., Owens P., Feoktistov I., Moses H.L., Novitskiy S.V. Role of TGF-\u03b2 Signaling in Generation of CD39+ CD73+ Myeloid Cells in Tumors. J. Immunol. 2014;193:3155\u20133164. doi: 10.4049/jimmunol.1400578.", "ArticleIdList": ["10.4049/jimmunol.1400578", "PMC4157098", "25127858"]}, {"Citation": "Farkona S., Diamandis E.P., Blasutig I.M. Cancer Immunotherapy: The Beginning of the End of Cancer? BMC Med. 2016;14:1\u201318. doi: 10.1186/s12916-016-0623-5.", "ArticleIdList": ["10.1186/s12916-016-0623-5", "PMC4858828", "27151159"]}, {"Citation": "Jiang Y., Chen M., Nie H., Yuan Y. PD-1 and PD-L1 in Cancer Immunotherapy: Clinical Implications and Future Considerations. Hum. Vaccines Immunother. 2019;15:1111\u20131122. doi: 10.1080/21645515.2019.1571892.", "ArticleIdList": ["10.1080/21645515.2019.1571892", "PMC6605868", "30888929"]}, {"Citation": "Li J.-X., Huang J.-M., Jiang Z.-B., Li R.-Z., Sun A., Lai-Han Leung E., Yan P.-Y. Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non\u2013Small Cell Lung Cancer. Integr. Cancer Ther. 2019;18:1534735419890020. doi: 10.1177/1534735419890020.", "ArticleIdList": ["10.1177/1534735419890020", "PMC7242804", "31838881"]}, {"Citation": "McDermott D.F., Atkins M.B. PD-1 as a Potential Target in Cancer Therapy. Cancer Med. 2013;2:662\u2013673. doi: 10.1002/cam4.106.", "ArticleIdList": ["10.1002/cam4.106", "PMC3892798", "24403232"]}, {"Citation": "O\u2019Donnell J.S., Smyth M.J., Teng M.W. Acquired Resistance to Anti-PD1 Therapy: Checkmate to Checkpoint Blockade? Genome Med. 2016;8:1\u20133. doi: 10.1186/s13073-016-0365-1.", "ArticleIdList": ["10.1186/s13073-016-0365-1", "PMC5080691", "27782862"]}, {"Citation": "Murciano-Goroff Y.R., Warner A.B., Wolchok J.D. The Future of Cancer Immunotherapy: Microenvironment-Targeting Combinations. Cell Res. 2020;30:507\u2013519. doi: 10.1038/s41422-020-0337-2.", "ArticleIdList": ["10.1038/s41422-020-0337-2", "PMC7264181", "32467593"]}, {"Citation": "Ventola C.L. Cancer Immunotherapy, Part 3: Challenges and Future Trends. Pharm. Ther. 2017;42:514.", "ArticleIdList": ["PMC5521300", "28781505"]}, {"Citation": "Chang J.T., Wherry E.J., Goldrath A.W. Molecular Regulation of Effector and Memory T Cell Differentiation. Nat. Immunol. 2014;15:1104\u20131115. doi: 10.1038/ni.3031.", "ArticleIdList": ["10.1038/ni.3031", "PMC4386685", "25396352"]}, {"Citation": "Hargadon K.M., Johnson C.E., Williams C.J. Immune Checkpoint Blockade Therapy for Cancer: An Overview of FDA-Approved Immune Checkpoint Inhibitors. Int. Immunopharmacol. 2018;62:29\u201339. doi: 10.1016/j.intimp.2018.06.001.", "ArticleIdList": ["10.1016/j.intimp.2018.06.001", "29990692"]}, {"Citation": "Jutel M., Akdis M., Blaser K., Akdis C.A. Mechanisms of Allergen Specific Immunotherapy\u2013T-Cell Tolerance and More. Allergy. 2006;61:796\u2013807. doi: 10.1111/j.1398-9995.2006.01175.x.", "ArticleIdList": ["10.1111/j.1398-9995.2006.01175.x", "16792576"]}, {"Citation": "Yu C.-C., Hung S.-K., Lin H.-Y., Chiou W.-Y., Lee M.-S., Liao H.-F., Huang H.-B., Ho H.-C., Su Y.-C. Targeting the PI3K/AKT/MTOR Signaling Pathway as an Effectively Radiosensitizing Strategy for Treating Human Oral Squamous Cell Carcinoma in Vitro and in Vivo. Oncotarget. 2017;8:68641. doi: 10.18632/oncotarget.19817.", "ArticleIdList": ["10.18632/oncotarget.19817", "PMC5620284", "28978144"]}, {"Citation": "Yu L., Wei J., Liu P. Seminars in Cancer Biology. Elsevier; Amsterdam, The Netherlands: 2021. Attacking the PI3K/Akt/MTOR Signaling Pathway for Targeted Therapeutic Treatment in Human Cancer.", "ArticleIdList": ["34175443"]}, {"Citation": "Wang Y., Wang X.Y., Subjeck J.R., Shrikant P.A., Kim H.L. Temsirolimus, an MTOR Inhibitor, Enhances Anti-Tumour Effects of Heat Shock Protein Cancer Vaccines. Br. J. Cancer. 2011;104:643\u2013652. doi: 10.1038/bjc.2011.15.", "ArticleIdList": ["10.1038/bjc.2011.15", "PMC3049595", "21285988"]}, {"Citation": "Diken M., Kreiter S., Vascotto F., Selmi A., Attig S., Diekmann J., Huber C., T\u00fcreci \u00d6., Sahin U. MTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNAmTOR Inhibition by Rapamycin Augments RNA Vaccine Efficacy. Cancer Immunol. Res. 2013;1:386\u2013392. doi: 10.1158/2326-6066.CIR-13-0046.", "ArticleIdList": ["10.1158/2326-6066.CIR-13-0046", "24778131"]}, {"Citation": "Chaoul N., Fayolle C., Desrues B., Oberkampf M., Tang A., Ladant D., Leclerc C. Rapamycin Impairs Antitumor CD8+ T-Cell Responses and Vaccine-Induced Tumor EradicationRapamycin Impedes Vaccine-Induced Tumor Rejection. Cancer Res. 2015;75:3279\u20133291. doi: 10.1158/0008-5472.CAN-15-0454.", "ArticleIdList": ["10.1158/0008-5472.CAN-15-0454", "26122844"]}, {"Citation": "Langdon S., Hughes A., Taylor M.A., Kuczynski E.A., Mele D.A., Delpuech O., Jarvis L., Staniszewska A., Cosulich S., Carnevalli L.S. Combination of Dual MTORC1/2 Inhibition and Immune-Checkpoint Blockade Potentiates Anti-Tumour Immunity. Oncoimmunology. 2018;7:e1458810. doi: 10.1080/2162402X.2018.1458810.", "ArticleIdList": ["10.1080/2162402X.2018.1458810", "PMC6136876", "30221055"]}, {"Citation": "Wang Y., Sparwasser T.L., Figlin R., Kim H.L. Abstract LB-260: Combination of Foxp3+ T Cells Depletion and MTOR Inhibitor Enhances Immune Memory and Controls Cancer Growth. Cancer Res. 2014;74:LB-260. doi: 10.1158/1538-7445.AM2014-LB-260.", "ArticleIdList": ["10.1158/1538-7445.AM2014-LB-260"]}, {"Citation": "Lastwika K.J., Wilson W., Li Q.K., Norris J., Xu H., Ghazarian S.R., Kitagawa H., Kawabata S., Taube J.M., Yao S. Control of PD-L1 Expression by Oncogenic Activation of the AKT\u2013MTOR Pathway in Non\u2013Small Cell Lung CancerControl of PD-L1 by Oncogenic Activation of AKT/MTOR in NSCLC. Cancer Res. 2016;76:227\u2013238. doi: 10.1158/0008-5472.CAN-14-3362.", "ArticleIdList": ["10.1158/0008-5472.CAN-14-3362", "26637667"]}, {"Citation": "Li H., Li X., Liu S., Guo L., Zhang B., Zhang J., Ye Q. PD-1 Checkpoint Blockade in Combination with an MTOR Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1. Hepatology. 2017;66:1920\u20131933. doi: 10.1002/hep.29360.", "ArticleIdList": ["10.1002/hep.29360", "28732118"]}, {"Citation": "Jiang Q., Weiss J.M., Back T., Chan T., Ortaldo J.R., Guichard S., Wiltrout R.H. MTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer TreatmentAntitumor Effect of AZD8055/ACD40. Cancer Res. 2011;71:4074\u20134084. doi: 10.1158/0008-5472.CAN-10-3968.", "ArticleIdList": ["10.1158/0008-5472.CAN-10-3968", "PMC3116937", "21540234"]}, {"Citation": "Wu J., Zhao X., Sun Q., Jiang Y., Zhang W., Luo J., Li Y. Synergic Effect of PD-1 Blockade and Endostar on the PI3K/AKT/MTOR-Mediated Autophagy and Angiogenesis in Lewis Lung Carcinoma Mouse Model. Biomed. Pharmacother. 2020;125:109746. doi: 10.1016/j.biopha.2019.109746.", "ArticleIdList": ["10.1016/j.biopha.2019.109746", "32106386"]}, {"Citation": "Ingels A., Zhao H., Thong A.E., Saar M., Valta M.P., Nolley R., Santos J., Peehl D.M. Preclinical Trial of a New Dual MTOR Inhibitor, MLN0128, Using Renal Cell Carcinoma Tumorgrafts. Int. J. Cancer. 2014;134:2322\u20132329. doi: 10.1002/ijc.28579.", "ArticleIdList": ["10.1002/ijc.28579", "PMC4365782", "24243565"]}, {"Citation": "Beziaud L., Boullerot L., Tran T., Mansi L., Marie-Joseph E.L., Ravel P., Johannes L., Bayry J., Tartour E., Adot\u00e9vi O. Rapalog Combined with CCR4 Antagonist Improves Anticancer Vaccines Efficacy. Int. J. Cancer. 2018;143:3008\u20133018. doi: 10.1002/ijc.31842.", "ArticleIdList": ["10.1002/ijc.31842", "30183073"]}, {"Citation": "Knutson K.L., Disis M.L. Tumor Antigen-Specific T Helper Cells in Cancer Immunity and Immunotherapy. Cancer Immunol. Immunother. 2005;54:721\u2013728. doi: 10.1007/s00262-004-0653-2.", "ArticleIdList": ["10.1007/s00262-004-0653-2", "16010587"]}, {"Citation": "Chen Y.-L., Lin H.-W., Sun N.-Y., Yie J.-C., Hung H.-C., Chen C.-A., Sun W.-Z., Cheng W.-F. MTOR Inhibitors Can Enhance the Anti-Tumor Effects of DNA Vaccines through Modulating Dendritic Cell Function in the Tumor Microenvironment. Cancers. 2019;11:617. doi: 10.3390/cancers11050617.", "ArticleIdList": ["10.3390/cancers11050617", "PMC6562783", "31052575"]}, {"Citation": "Kaufman H.L. Seminars in Oncology. Volume 39. Elsevier; Amsterdam, The Netherlands: 2012. Vaccines for Melanoma and Renal Cell Carcinoma; pp. 263\u2013275.", "ArticleIdList": ["22595049"]}, {"Citation": "O\u2019Donnell J.S., Massi D., Teng M.W., Mandala M. Seminars in Cancer Biology. Volume 48. Elsevier; Amsterdam, The Netherlands: 2018. PI3K-AKT-MTOR Inhibition in Cancer Immunotherapy, Redux; pp. 91\u2013103.", "ArticleIdList": ["28467889"]}, {"Citation": "El Hage A., Dormond O. Combining MTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment. Cancers. 2021;13:1359. doi: 10.3390/cancers13061359.", "ArticleIdList": ["10.3390/cancers13061359", "PMC8002586", "33802831"]}, {"Citation": "Shor B., Zhang W.-G., Toral-Barza L., Lucas J., Abraham R.T., Gibbons J.J., Yu K. A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of MTOR Kinase Activity and Profound Repression of Global Protein Synthesis. Cancer Res. 2008;68:2934\u20132943. doi: 10.1158/0008-5472.CAN-07-6487.", "ArticleIdList": ["10.1158/0008-5472.CAN-07-6487", "18413763"]}, {"Citation": "Yang H., Rudge D.G., Koos J.D., Vaidialingam B., Yang H.J., Pavletich N.P. MTOR Kinase Structure, Mechanism and Regulation. Nature. 2013;497:217\u2013223. doi: 10.1038/nature12122.", "ArticleIdList": ["10.1038/nature12122", "PMC4512754", "23636326"]}, {"Citation": "Gotwals P., Cameron S., Cipolletta D., Cremasco V., Crystal A., Hewes B., Mueller B., Quaratino S., Sabatos-Peyton C., Petruzzelli L. Prospects for Combining Targeted and Conventional Cancer Therapy with Immunotherapy. Nat. Rev. Cancer. 2017;17:286\u2013301. doi: 10.1038/nrc.2017.17.", "ArticleIdList": ["10.1038/nrc.2017.17", "28338065"]}, {"Citation": "Rowshanravan B., Halliday N., Sansom D.M. CTLA-4: A Moving Target in Immunotherapy. Blood J. Am. Soc. Hematol. 2018;131:58\u201367. doi: 10.1182/blood-2017-06-741033.", "ArticleIdList": ["10.1182/blood-2017-06-741033", "PMC6317697", "29118008"]}, {"Citation": "Pedicord V.A., Cross J.R., Montalvo-Ortiz W., Miller M.L., Allison J.P. Friends Not Foes: CTLA-4 Blockade and MTOR Inhibition Cooperate during CD8+ T Cell Priming to Promote Memory Formation and Metabolic Readiness. J. Immunol. 2015;194:2089\u20132098. doi: 10.4049/jimmunol.1402390.", "ArticleIdList": ["10.4049/jimmunol.1402390", "25624453"]}, {"Citation": "Alsaab H.O., Sau S., Alzhrani R., Tatiparti K., Bhise K., Kashaw S.K., Iyer A.K. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front. Pharmacol. 2017;8:561. doi: 10.3389/fphar.2017.00561.", "ArticleIdList": ["10.3389/fphar.2017.00561", "PMC5572324", "28878676"]}, {"Citation": "Chen L., Han X. Anti-PD-1PD-L1 Ther. Hum. Cancer Past Present Future. J. Clin. Investig. 2015;125:3384\u20133391.", "ArticleIdList": ["PMC4588282", "26325035"]}, {"Citation": "Lastwika K.J. Ph.D. Thesis. The George Washington University; Washington, DC, USA: 2014. Regulation and Consequences of PD-L1 Expression in Non-Small Cell Lung Cancer."}, {"Citation": "Mittendorf E.A., Philips A.V., Meric-Bernstam F., Qiao N., Wu Y., Harrington S., Su X., Wang Y., Gonzalez-Angulo A.M., Akcakanat A. PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunol. Res. 2014;2:361\u2013370. doi: 10.1158/2326-6066.CIR-13-0127.", "ArticleIdList": ["10.1158/2326-6066.CIR-13-0127", "PMC4000553", "24764583"]}, {"Citation": "Wu K., Yi M., Qin S., Chu Q., Zheng X., Wu K. The Efficacy and Safety of Combination of PD-1 and CTLA-4 Inhibitors: A Meta-Analysis. Exp. Hematol. Oncol. 2019;8:1\u201312. doi: 10.1186/s40164-019-0150-0.", "ArticleIdList": ["10.1186/s40164-019-0150-0", "PMC6815037", "31673481"]}, {"Citation": "Jarosz-Biej M., Smolarczyk R., Cicho\u0144 T., Ku\\lach N. Tumor Microenvironment as a \u201cGame Changer\u201d in Cancer Radiotherapy. Int. J. Mol. Sci. 2019;20:3212. doi: 10.3390/ijms20133212.", "ArticleIdList": ["10.3390/ijms20133212", "PMC6650939", "31261963"]}, {"Citation": "Lindau D., Gielen P., Kroesen M., Wesseling P., Adema G.J. The Immunosuppressive Tumour Network: Myeloid-Derived Suppressor Cells, Regulatory T Cells and Natural Killer T Cells. Immunology. 2013;138:105\u2013115. doi: 10.1111/imm.12036.", "ArticleIdList": ["10.1111/imm.12036", "PMC3575763", "23216602"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "10", "Day": "4"}, {"Year": "2022", "Month": "11", "Day": "1"}, {"Year": "2022", "Month": "11", "Day": "2"}, {"Year": "2022", "Month": "11", "Day": "26", "Hour": "1", "Minute": "4"}, {"Year": "2022", "Month": "11", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "11", "Day": "27", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "11", "Day": "10"}], "PublicationStatus": "epublish", "ArticleIdList": ["36428613", "PMC9688668", "10.3390/cancers14225520", "cancers14225520"]}}], "PubmedBookArticle": []}